<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Porokeratosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Porokeratosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Porokeratosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laurence Imhof, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Egle Ramelyte, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reinhard G Dummer, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">June K Robinson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2260502"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Porokeratosis is a rare, acquired or inherited disorder of keratinization characterized by one or more atrophic macules or patches, each surrounded by a distinctive hyperkeratotic, ridge-like border called a "cornoid lamella"  (<a class="graphic graphic_picture graphicRef62674 graphicRef62258" href="/d/graphic/62674.html" rel="external">picture 1A-B</a>) [<a href="#rid1">1,2</a>]. Multiple clinical variants of porokeratosis exist. Malignant transformation occurs in a minority of cases.</p><p>Although clinical surveillance for malignant transformation is sufficient for the management of most patients with porokeratosis, patients who are concerned about the appearance of lesions or who have associated symptoms, such as pruritus or pain, may desire therapeutic intervention. Formal studies of the therapeutic options for porokeratosis are lacking, but various topical, surgical, destructive, and systemic therapies appear to be effective in some patients.</p><p>The pathogenesis, clinical manifestations, diagnosis, and management of porokeratosis will be reviewed here. </p><p class="headingAnchor" id="H1382130319"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Porokeratosis is a rare disease. The exact incidence and prevalence are not known. It typically occurs in adults or older adults with slight male predominance, but pediatric cases have been reported [<a href="#rid3">3-7</a>].</p><p class="headingAnchor" id="H959602"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The most commonly described variants of porokeratosis include: </p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated superficial actinic porokeratosis (DSAP1; MIM #175900, 616063, 614714, 616631)</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated superficial porokeratosis (DSP; MIM #175900, 616631)</p><p class="bulletIndent1"><span class="glyph">●</span>Eruptive disseminated porokeratosis</p><p class="bulletIndent1"><span class="glyph">●</span>Porokeratosis of Mibelli (MIM #175800)</p><p class="bulletIndent1"><span class="glyph">●</span>Linear porokeratosis</p><p class="bulletIndent1"><span class="glyph">●</span>Porokeratosis palmaris et plantaris disseminata (PPPD; MIM #175850)</p><p class="bulletIndent1"><span class="glyph">●</span>Punctate porokeratosis (sometimes considered a variant of PPPD)</p><p class="bulletIndent1"><span class="glyph">●</span>Porokeratosis ptychotropica </p><p class="bulletIndent1"><span class="glyph">●</span>Genitogluteal porokeratosis</p><p></p><p>Most clinical types of porokeratosis can manifest in localized or generalized forms; however, overlap between the forms as well as clinical variants are not uncommon. </p><p class="headingAnchor" id="H725539"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The clonal proliferation of abnormal epidermal keratinocytes is believed to account for the clinical manifestations of porokeratosis. However, the pathway that leads to this process remains unknown. A variety of factors have been proposed as potential contributors, including genetic susceptibility, ultraviolet radiation, and immune status.</p><p class="headingAnchor" id="H959617"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Inherited or de novo genetic defects likely play an important role in porokeratosis. Studies in familial cases of disseminated superficial actinic porokeratosis (DSAP) support an autosomal dominant inheritance pattern with incomplete penetrance [<a href="#rid8">8</a>].</p><p>Four potential chromosomal loci for DSAP have been identified, including DSAP1 (12q23.2-24.1), DSAP2 (15q25.1-26.1), DSAP3 (1p31.3-p31.1), and DSAP4 (16q24.1-24.3) [<a href="#rid9">9-12</a>]. In Chinese studies, mutations in the phosphomevalonate kinase pathway genes, namely mevalonate decarboxylase (<em>MVD</em>), mevalonate kinase<em> </em>(<em>MVK</em>), phosphomevalonate kinase (<em>PMVK</em>), and farnesyl diphosphate synthase (<em>FDPS</em>), have been detected in some patients with porokeratosis [<a href="#rid13">13,14</a>]. There are over 200 mutations identified so far [<a href="#rid14">14-17</a>]. At least one mutation in the mevalonate pathway genes was reported to be found in up to 98 percent of the familial and over 70 percent of sporadic porokeratosis cases [<a href="#rid18">18</a>].</p><p>The mevalonate pathway genes are involved in the biosynthesis of isoprenoids, which are precursors of multiple biologically important substances, such as cholesterol, and are indirectly involved in biologic events, such as cell growth of differentiation. It is thus hypothesized that mutations in mevalonate pathway result in accumulation of abnormal cell metabolites, retention of cell nuclei in the epidermis, and formation of the cornoid lamella [<a href="#rid18">18,19</a>]. Moreover, inhibition of enzymes within the mevalonate pathway leads to decreased expression of keratinocyte differentiation marker involucrin, p53 and Notch1, further supporting the causative relationship between mutations in mevalonate pathway and development of porokeratosis [<a href="#rid20">20</a>].</p><p>Familial cases of disseminated superficial porokeratosis (DSP) and porokeratosis plantaris palmaris et disseminata (PPPD) demonstrate autosomal dominant inheritance patterns. The loci linked to DSP and PPPD are on chromosome 18p11.3 and chromosome 12q24.1-24.2, respectively [<a href="#rid21">21-23</a>].</p><p>Focal forms of porokeratosis, such as porokeratosis of Mibelli and linear porokeratosis, may occur as a consequence of mosaicism. The occurrence of linear porokeratosis or porokeratosis of Mibelli in patients with DSAP has been attributed to this theory [<a href="#rid8">8,24</a>]. In such cases, focal loss of heterozygosity via somatic mutations may result in the prominent, localized clinical manifestations that characterize linear porokeratosis and porokeratosis of Mibelli, while the relatively milder manifestations of DSAP appear in a generalized distribution [<a href="#rid8">8,24,25</a>]. (See  <a class="medical medical_review" href="/d/html/2897.html" rel="external">"Inheritance patterns of monogenic disorders (Mendelian and non-Mendelian)", section on 'Mosaicism'</a>.)</p><p class="headingAnchor" id="H959624"><span class="h2">Ultraviolet radiation</span><span class="headingEndMark"> — </span>Exposure to ultraviolet radiation may contribute to the development of porokeratosis. This assertion is supported by the observation that DSAP preferentially occurs on areas of exposed skin and in individuals with histories of extensive sun exposure. In addition, the administration of artificial ultraviolet light in experimental and therapeutic settings has resulted in the induction of DSAP lesions [<a href="#rid26">26-29</a>].</p><p>Despite these findings, a definitive role for ultraviolet radiation in porokeratosis remains uncertain. Improvement in DSAP after treatment with psoralen plus ultraviolet A (PUVA) therapy has been documented in one patient [<a href="#rid30">30</a>]. The relative sparing of the face in DSAP also raises questions about the designation of ultraviolet radiation as a contributory factor. (See <a class="local">'Disseminated superficial actinic porokeratosis'</a> below.)</p><p class="headingAnchor" id="H959631"><span class="h2">Immunosuppression</span><span class="headingEndMark"> — </span>Drug-induced immunosuppression or immunodeficiency in the setting of nonmalignant diseases or hematologic malignancy may increase the risk for porokeratosis [<a href="#rid31">31-37</a>]. Estimates of the prevalence of porokeratosis in immunosuppressed organ transplant recipients range from less than 1 percent to as high as 11 percent [<a href="#rid33">33,36</a>]. </p><p>Porokeratosis has occurred 3 weeks to 14 years after the initiation of systemic immunosuppression [<a href="#rid36">36,38</a>]. DSP and porokeratosis of Mibelli are the most commonly associated variants [<a href="#rid39">39</a>]. A rapidly evolving form of porokeratosis, called eruptive disseminated porokeratosis, has been described in older patients, in association with solid cancers or immunosuppressive therapy [<a href="#rid40">40</a>].</p><p>New-onset DSP and porokeratosis of Mibelli have been reported in patients with known HIV infection and may indicate a worsening of the immunodeficiency [<a href="#rid32">32,41</a>]. </p><p>A contributory role for immunosuppression is supported by reports of remission of porokeratosis after cessation of immunosuppressive therapy in two patients [<a href="#rid42">42,43</a>]. The development of porokeratosis in sites of long-term potent topical corticosteroid use in another patient also suggests a role for immunosuppression [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H959795"><span class="h2">Other</span><span class="headingEndMark"> — </span>Additional factors that have been associated with porokeratosis include radiation therapy [<a href="#rid45">45,46</a>], trauma [<a href="#rid47">47</a>], liver disease [<a href="#rid48">48,49</a>], solid organ cancer [<a href="#rid50">50,51</a>], and Crohn's disease [<a href="#rid52">52</a>]. Cases of drug-induced porokeratosis have also been reported following treatments with <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> and <a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">hydroxyurea</a> [<a href="#rid53">53-55</a>].</p><p class="headingAnchor" id="H725547"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The defining feature of porokeratosis is the clinical and histopathologic presence of a cornoid lamella, which typically manifests as a thin, keratotic rim at the periphery of a slightly atrophic skin lesion  (<a class="graphic graphic_picture graphicRef62258" href="/d/graphic/62258.html" rel="external">picture 1B</a>). Lesions typically begin as small, keratotic papules that spread slowly and centrifugally [<a href="#rid39">39</a>].</p><p>Multiple clinical variants have been described. Disseminated superficial actinic porokeratosis (DSAP) is generally accepted to be the most common variant, followed by porokeratosis of Mibelli. In one series of 94 patients in Singapore, classic porokeratosis of Mibelli, DSAP, disseminated superficial porokeratosis (DSP), and linear porokeratosis accounted for 56, 18, 11, and 13 percent of cases of porokeratosis, respectively [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H725555"><span class="h2">Disseminated superficial actinic porokeratosis</span><span class="headingEndMark"> — </span>Disseminated superficial actinic porokeratosis (DSAP) is the most common type of porokeratosis. DSAP occurs more frequently in women than men, with an estimated female to male ratio of approximately 1.8:1 [<a href="#rid39">39</a>]. The onset of disease typically occurs in the third or fourth decade of life, and patients frequently report a history of extensive exposure to natural or artificial ultraviolet radiation. Worsening of disease during the summer months may occur [<a href="#rid39">39</a>].</p><p>DSAP is characterized by erythematous, skin-colored or hyperpigmented, well-defined macules that are typically less than 1 cm in diameter  (<a class="graphic graphic_picture graphicRef59742 graphicRef81874 graphicRef80248" href="/d/graphic/59742.html" rel="external">picture 2A-C</a>). The cornoid lamella is often subtle, manifesting as a fine, peripheral, keratotic ridge. The distribution of lesions typically involves the extensor surfaces of the arms, legs, shoulders, or back, with sparing of the palms and soles. Facial lesions, a less common finding, occur in approximately 15 percent of patients [<a href="#rid56">56</a>]. A less common variant (inflammatory DSAP) presents as erythematous lesions, accompanied by inflammation and severe pruritus [<a href="#rid57">57</a>].</p><p>The number of skin lesions in DSAP is variable. Only a few or several hundred lesions may be present [<a href="#rid30">30</a>]. The cosmetic appearance of DSAP is a common concern for patients with this disorder and may be particularly bothersome for individuals who frequently wear skirts or shorts that expose the lower legs. Skin lesions are often asymptomatic, but pruritus or stinging sensations are estimated to occur in one-third to one-half of patients [<a href="#rid30">30,39</a>]. </p><p class="headingAnchor" id="H726119"><span class="h2">Disseminated superficial porokeratosis</span><span class="headingEndMark"> — </span>Disseminated superficial porokeratosis (DSP) resembles DSAP but lacks photodistribution, appearing in both sun-exposed and non-sun-exposed sites. Like DSAP, the palms and soles are typically spared.</p><p>In contrast to DSAP, DSP often develops in childhood, most commonly between the ages of 5 and 10 years [<a href="#rid39">39</a>]. As noted above, DSP also can occur in association with immunosuppression [<a href="#rid58">58-60</a>] (see <a class="local">'Immunosuppression'</a> above). In addition, DSP has been reported in a few patients with solid organ malignancies [<a href="#rid50">50,51</a>]. </p><p class="headingAnchor" id="H4090103592"><span class="h2">Eruptive disseminated porokeratosis</span><span class="headingEndMark"> — </span>The term "eruptive disseminated porokeratosis" has been proposed for adult-onset, acute disseminated porokeratosis, which has a male preponderance and may show variable morphology [<a href="#rid40">40</a>]. Most patients with adult-onset DSP are immunosuppressed or have a coexisting internal malignancy. </p><p class="headingAnchor" id="H725563"><span class="h2">Porokeratosis of Mibelli</span><span class="headingEndMark"> — </span>Porokeratosis of Mibelli is the second most common type of porokeratosis [<a href="#rid3">3</a>]. The disorder often begins in childhood and affects males approximately twice as frequently as females [<a href="#rid39">39</a>]. Occasionally, lesions develop during adulthood, often in association with immunosuppression [<a href="#rid32">32,34,36,61</a>]. </p><p>Porokeratosis of Mibelli typically begins as a small, asymptomatic or slightly pruritic papule that slowly expands over the course of years  (<a class="graphic graphic_picture graphicRef81011 graphicRef62674 graphicRef78667" href="/d/graphic/81011.html" rel="external">picture 1A, 1C-D</a>). Faster growth may occur in the setting of immunosuppression. Well-developed lesions are usually a few centimeters in diameter, and, rarely, lesions grow to 10 to 20 cm in size. The term "giant porokeratosis" has been used to describe these exceptionally large lesions [<a href="#rid62">62,63</a>]. The cornoid lamella is often prominent in lesions of porokeratosis of Mibelli. The lesion border is usually greater than 1 mm in height, and a thin furrow is typically seen in the center of the ridge, causing an appearance that resembles the Great Wall of China  (<a class="graphic graphic_picture graphicRef81011" href="/d/graphic/81011.html" rel="external">picture 1C</a>). The center of the lesion may be slightly hypopigmented or hyperpigmented, minimally scaly, slightly atrophic, and hairless. Uncommonly, lesions manifest as confluent, hyperkeratotic or verrucous, thick plaques [<a href="#rid64">64,65</a>].</p><p>The classic location for porokeratosis of Mibelli is on an extremity. However, lesions may occur in any site, including the palms, soles, genitalia, or mucous membranes [<a href="#rid39">39,66,67</a>]. Patients usually present with a solitary lesion or a few asymmetrically distributed lesions. Occasionally, widespread lesions occur [<a href="#rid24">24,62,64</a>]. Involvement of the distal portions of fingers and toes may result in dystrophy and/or complete loss of the nail [<a href="#rid68">68</a>].</p><p class="headingAnchor" id="H725578"><span class="h2">Linear porokeratosis</span><span class="headingEndMark"> — </span>Linear porokeratosis is a rare form of porokeratosis that may represent a segmental form of DSAP or DSP [<a href="#rid8">8,24</a>]. The skin lesions typically present during infancy or early childhood but occasionally develop in adults. Females are slightly more likely to be affected than males [<a href="#rid36">36</a>]. </p><p>Based on the distribution of the lesions, linear porokeratosis can be subdivided into localized, zosteriform, systematized, or generalized variants  (<a class="graphic graphic_picture graphicRef73545 graphicRef50928" href="/d/graphic/73545.html" rel="external">picture 3A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized</strong> – The localized variant of linear porokeratosis presents as single or multiple plaques with hyperkeratotic, peripheral rims on one extremity. The lesions may initially be flat and become more prominent with time. As in porokeratosis of Mibelli, the hyperkeratotic border is often prominent, and a furrow is seen just inside of the hyperkeratotic ridge.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Zosteriform</strong> – In the zosteriform variant, the configuration of lesions usually follows the lines of Blaschko  (<a class="graphic graphic_figure graphicRef57219" href="/d/graphic/57219.html" rel="external">figure 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systematized </strong>– Systematized linear porokeratosis presents as lesions distributed on the upper and lower extremities of one body side.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized</strong> – In the generalized form of linear porokeratosis, lesions are found on more than one extremity or on the trunk.</p><p></p><p>Linear porokeratosis is associated with increased risk of squamous cell carcinoma [<a href="#rid69">69-72</a>]. (See <a class="local">'Malignant transformation'</a> below.)</p><p class="headingAnchor" id="H117566455"><span class="h2">Porokeratosis plantaris palmaris et disseminata</span><span class="headingEndMark"> — </span>Porokeratosis plantaris palmaris et disseminata (PPPD) is a rare variant of porokeratosis, inherited in an autosomal dominant pattern, that may develop at any age [<a href="#rid3">3,73</a>]. Lesions customarily first appear in adolescence or early adulthood.</p><p>The initial manifestations of PPPD are multiple small, relatively uniform macules on the palms and soles that exhibit a slightly hyperpigmented and atrophic center and a minimally raised peripheral ridge [<a href="#rid73">73-76</a>]. A serpiginous configuration may evolve over time. Patients with PPPD can also develop lesions on the trunk and extremities that resemble lesions of DSAP and DSP  (<a class="graphic graphic_picture graphicRef135139" href="/d/graphic/135139.html" rel="external">picture 4</a>). Involvement of the oral mucosa may also occur as multiple small, depressed, opalescent rings with hyperemic borders [<a href="#rid77">77</a>].</p><p>The lesions of PPPD may be asymptomatic, pruritic, or tender to palpation. Porokeratoses on the feet may cause discomfort with walking.</p><p class="headingAnchor" id="H959736"><span class="h3">Punctate porokeratosis</span><span class="headingEndMark"> — </span>Punctate porokeratosis (porokeratosis punctata palmaris et plantaris) is characterized by multiple small, seed-like, keratotic lesions on the palms and soles  (<a class="graphic graphic_picture graphicRef135139" href="/d/graphic/135139.html" rel="external">picture 4</a>) that have histopathologic findings consistent with a cornoid lamella [<a href="#rid78">78,79</a>]. Some authors consider punctate porokeratosis to be a forme fruste of PPPD rather than a separate entity.</p><p class="headingAnchor" id="H190517"><span class="h2">Porokeratosis ptychotropica</span><span class="headingEndMark"> — </span>Porokeratosis ptychotropica is an unusual psoriasiform variant of the disease, also described as verrucous and hypertrophic porokeratosis [<a href="#rid80">80-82</a>]. This type of porokeratosis typically presents in male patients with inflammatory, keratotic, or verrucous plaques on the buttocks or genital skin  (<a class="graphic graphic_picture graphicRef53110 graphicRef61803" href="/d/graphic/53110.html" rel="external">picture 5A-B</a>). Pathology shows numerous histopathologic foci of cornoid lamellae [<a href="#rid80">80,81,83</a>]. Lesions of porokeratosis ptychotropica are often mistaken for psoriasis, lichen simplex chronicus, or chronic eczema not only due to clinical similarities but also due to itching.</p><p class="headingAnchor" id="H2489815107"><span class="h2">Genitogluteal porokeratosis</span><span class="headingEndMark"> — </span>The genital area is uncommonly affected by porokeratosis, with approximately 50 cases reported in the literature [<a href="#rid84">84</a>]. The porokeratotic lesions in the genital area can either represent a separate entity or a localized form of other types of porokeratosis [<a href="#rid85">85</a>]. The genital involvement is more commonly reported in men; however, case reports of vulval porokeratosis have also been published.</p><p>Over 10 cases of penoscrotal porokeratosis have been published [<a href="#rid86">86,87</a>]. In this variant, the patients develop solitary or multiple lesions of variable size limited to the penile and/or scrotal skin. This uncommon variant of the disease has been reported to only occur in young men in their third decade of life, with clinical manifestation on the penile shaft and anterior scrotum accompanied by severe burning and itching  (<a class="graphic graphic_picture graphicRef135140" href="/d/graphic/135140.html" rel="external">picture 6</a>) [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H902096590"><span class="h2">Other</span><span class="headingEndMark"> — </span>Other subtypes of porokeratosis that have been described in the literature include follicular porokeratosis [<a href="#rid88">88-91</a>], eruptive pruritic papular porokeratosis in the setting of DSP [<a href="#rid92">92-94</a>], giant porokeratosis (see <a class="local">'Porokeratosis of Mibelli'</a> above), filiform porokeratosis [<a href="#rid95">95</a>], and porokeratosis associated with CDAGS (craniosynostosis, delayed closure of the fontanel, cranial defects, clavicular hypoplasia, anal and genitourinary malformations, and skin eruption) syndrome [<a href="#rid96">96,97</a>].</p><p class="headingAnchor" id="H702205814"><span class="h1">MALIGNANT TRANSFORMATION</span><span class="headingEndMark"> — </span>Malignant transformation may occur in patients with all clinical variants of porokeratosis, with the exception of punctate porokeratosis [<a href="#rid98">98</a>]. It is estimated to occur in 7.5 to 11 percent of patients, with an average period to cancer onset of 36 years [<a href="#rid39">39</a>]. Squamous cell carcinoma is the most common associated malignancy [<a href="#rid99">99</a>]. Basal cell carcinoma and Bowen disease (squamous cell carcinoma in situ) may also occur.</p><p>Linear porokeratosis and giant porokeratosis (a variant of porokeratosis of Mibelli) are the variants most susceptible to malignant transformation, while this occurrence in disseminated superficial actinic porokeratosis (DSAP) is less common [<a href="#rid98">98,100,101</a>]. One review of 281 patients with porokeratosis found risks for malignant transformation in patients with linear porokeratosis, porokeratosis plantaris palmaris et disseminata (PPPD), porokeratosis of Mibelli of any size, and DSAP of 19, 10, 8, and 3 percent, respectively [<a href="#rid98">98</a>]. However, as development of DSAP might be ultraviolet light dependent and ultraviolet irradiation causes development of cutaneous malignancies, concurrent presentation of DSAP, actinic keratoses, and other cutaneous malignancies is not infrequent. Large lesion size, location on the extremities, and long lesion duration are additional factors that have been identified as risk factors for malignant transformation [<a href="#rid39">39,98,102,103</a>].</p><p class="headingAnchor" id="H725594"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Due to a distinct clinical presentation, diagnosis is often made by clinical inspection. Dermoscopy can support the clinical diagnosis [<a href="#rid104">104</a>]. However, histology along with clinical suspicion provides the most accurate diagnosis.</p><p class="headingAnchor" id="H3094966174"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The diagnosis of porokeratosis often can be made based solely on clinical examination. The clinical appearance of an atrophic macule or patch with a well-defined, raised, hyperkeratotic ridge suggests this disorder  (<a class="graphic graphic_picture graphicRef62258" href="/d/graphic/62258.html" rel="external">picture 1B</a>). Marker ink or iodine can be used to highlight the appearance of the cornoid lamella in subtle cases. Self-tanning lotions containing dihydroxyacetone also highlight the cornoid lamella.</p><p>Skin biopsies usually are not necessary. Biopsies are typically performed when the appearance of the lesion is not classic or when there is concern for malignant transformation. (See <a class="local">'Histopathology'</a> below and <a class="local">'Differential diagnosis'</a> below.)</p><p class="headingAnchor" id="H725602"><span class="h2">Histopathology</span><span class="headingEndMark"> — </span>A shave biopsy deep enough to incorporate the mid-dermis is adequate for diagnosis, provided that it includes the edge of the lesion (site of the cornoid lamella). Small lesions may be removed entirely by shave excision. A punch biopsy of the lesion edge may also be performed. (See  <a class="medical medical_review" href="/d/html/5577.html" rel="external">"Skin biopsy techniques", section on 'Biopsy techniques'</a>.)</p><p>The classic histopathologic feature of porokeratosis is the cornoid lamella, a thin column of tightly packed parakeratotic cells within a keratin-filled epidermal invagination  (<a class="graphic graphic_picture graphicRef61211 graphicRef67831 graphicRef66289" href="/d/graphic/61211.html" rel="external">picture 7A-C</a>). The apex of the column angles away from the center of the lesion, and the base of the column demonstrates interruption of the epidermal granular layer and dyskeratotic keratinocytes [<a href="#rid36">36</a>]. A moderate lymphocytic inflammatory infiltrate is typically present in the papillary dermis. Dermal amyloid deposits are occasionally seen [<a href="#rid80">80,105,106</a>]. Melanocytic hyperplasia, with or without clinical hyperpigmentation, was noted in approximately 25 percent of specimens in one study [<a href="#rid107">107</a>].</p><p>Although the vast majority of biopsy specimens that demonstrate a cornoid lamella are derived from true porokeratoses, the finding is not exclusive to these lesions. Rarely, cornoid lamellae may be seen in other disorders, such as actinic keratoses, seborrheic keratoses, viral warts, and basal cell or squamous cell carcinoma [<a href="#rid108">108</a>].</p><p class="headingAnchor" id="H725610"><span class="h2">Dermoscopy</span><span class="headingEndMark"> — </span>Dermoscopy is a noninvasive test that can be useful for diagnosis if the clinician has access to the equipment and is trained in its use. (See  <a class="medical medical_review" href="/d/html/13521.html" rel="external">"Overview of dermoscopy"</a>.)</p><p>The most distinct dermoscopic feature is the keratin rim (the cornoid lamella) [<a href="#rid104">104</a>], which appears as a thin, white, double-marginated rim [<a href="#rid109">109-113</a>]. The atrophic center of a lesion often demonstrates a white area with glomerular or dotted vessels [<a href="#rid104">104,109</a>]. The less common dermatoscopic features involve nonperipheral scales, gray-brown dots, and pigmentation along or within the keratin rim [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H4264702588"><span class="h2">Additional evaluation</span><span class="headingEndMark"> — </span>The possibility of associated immunosuppression or internal malignancy (especially hematologic malignancy) should be considered in adults who present with new-onset porokeratosis of Mibelli or porokeratosis plantaris palmaris et disseminata (PPPD), or sudden exacerbations of a longstanding porokeratotic disorder.</p><p class="headingAnchor" id="H959986"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The detection of a cornoid lamella on clinical examination in a lesion suspicious for porokeratosis is usually sufficient for diagnosis. However, when patients present with less classic findings, other disorders that share clinical features with porokeratosis must be considered. In such cases, a biopsy of the lesion for histopathologic evaluation is helpful for distinguishing between porokeratosis and other disorders:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated superficial actinic porokeratosis</strong> – Lesions that clinically may resemble disseminated superficial actinic porokeratosis (DSAP) or disseminated superficial porokeratosis (DSP) include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple actinic keratoses  (<a class="graphic graphic_picture graphicRef53177" href="/d/graphic/53177.html" rel="external">picture 8</a>) (see  <a class="medical medical_review" href="/d/html/13712.html" rel="external">"Actinic keratosis: Epidemiology, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Macular seborrheic keratoses  (<a class="graphic graphic_picture graphicRef109669" href="/d/graphic/109669.html" rel="external">picture 9</a>) (see  <a class="medical medical_review" href="/d/html/5573.html" rel="external">"Overview of benign lesions of the skin", section on 'Seborrheic keratosis'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inflammatory skin disorders, such as guttate psoriasis, pityriasis rosea, nummular dermatitis, tinea corporis, and lichen planus  (<a class="graphic graphic_picture graphicRef55141 graphicRef57568 graphicRef96164 graphicRef55949 graphicRef68197" href="/d/graphic/55141.html" rel="external">picture 10A-E</a>) (see  <a class="medical medical_review" href="/d/html/15280.html" rel="external">"Guttate psoriasis"</a> and  <a class="medical medical_review" href="/d/html/5665.html" rel="external">"Pityriasis rosea"</a> and  <a class="medical medical_review" href="/d/html/13666.html" rel="external">"Nummular eczema"</a> and  <a class="medical medical_review" href="/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections", section on 'Tinea corporis'</a> and  <a class="medical medical_review" href="/d/html/5662.html" rel="external">"Lichen planus"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Porokeratosis of Mibelli</strong> – Lesions that clinically may resemble porokeratosis of Mibelli include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous squamous cell carcinoma in situ  (<a class="graphic graphic_picture graphicRef82358" href="/d/graphic/82358.html" rel="external">picture 11</a>) (see  <a class="medical medical_review" href="/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tinea corporis  (<a class="graphic graphic_picture graphicRef55949" href="/d/graphic/55949.html" rel="external">picture 10D</a>) (see  <a class="medical medical_review" href="/d/html/4030.html" rel="external">"Dermatophyte (tinea) infections"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Granuloma annulare  (<a class="graphic graphic_picture graphicRef73823" href="/d/graphic/73823.html" rel="external">picture 12</a>) (see  <a class="medical medical_review" href="/d/html/13705.html" rel="external">"Granuloma annulare: Epidemiology, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lichen simplex chronicus</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Circumscribed palmar or plantar hypokeratosis [<a href="#rid114">114</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous sarcoidosis [<a href="#rid115">115</a>] (see  <a class="medical medical_review" href="/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Linear porokeratosis</strong> – Lesions that clinically may resemble linear porokeratosis include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Linear warts (see  <a class="medical medical_review" href="/d/html/4029.html" rel="external">"Cutaneous warts (common, plantar, and flat warts)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lichen striatus  (<a class="graphic graphic_picture graphicRef89805 graphicRef95738 graphicRef94732 graphicRef89804 graphicRef94730" href="/d/graphic/89805.html" rel="external">picture 13A-E</a>) (see  <a class="medical medical_review" href="/d/html/13731.html" rel="external">"Lichen striatus"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Linear verrucous epidermal nevus  (<a class="graphic graphic_picture graphicRef89777" href="/d/graphic/89777.html" rel="external">picture 14</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Linear Darier disease (see  <a class="medical medical_review" href="/d/html/15462.html" rel="external">"Darier disease"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Porokeratotic adnexal osteal nevus (a proposed term that incorporates porokeratotic eccrine ostial and dermal duct nevus [PEODDN] and porokeratotic eccrine and hair follicle nevus [PEHFN]) [<a href="#rid116">116,117</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Porokeratosis palmaris plantaris/punctate porokeratosis</strong> – Several other disorders may present with discrete, keratotic lesions on the palms and soles mimicking porokeratosis plantaris palmaris et disseminata (PPPD) and punctate porokeratosis. Examples include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Arsenical keratoses  (<a class="graphic graphic_picture graphicRef120222" href="/d/graphic/120222.html" rel="external">picture 15</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palmoplantar keratodermas (see  <a class="medical medical_review" href="/d/html/110147.html" rel="external">"Palmoplantar keratoderma"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Palmar pits in basal cell nevus syndrome  (<a class="graphic graphic_picture graphicRef72687" href="/d/graphic/72687.html" rel="external">picture 16</a>) (see  <a class="medical medical_review" href="/d/html/5340.html" rel="external">"Nevoid basal cell carcinoma syndrome (Gorlin syndrome)"</a>)</p><p></p><p class="headingAnchor" id="H725618"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H1781911479"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Education about sun protection and clinical surveillance for malignant transformation are sufficient for the management of most patients with porokeratosis. However, patients who are concerned about the appearance of lesions or those with symptomatic disease (eg, pruritic or painful lesions) may desire therapeutic intervention.</p><p>Options for the treatment of porokeratosis include topical pharmacologic therapy, destructive therapies, surgical excision, and oral retinoids. Since no randomized trials have evaluated therapies for porokeratosis and the available data are insufficient for definitive recommendations on treatment, the choice of therapy is primarily based on factors such as lesion size and number, lesion location, aesthetic considerations, treatment availability, and patient preference. Our approach is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who desire quick therapy for a few small lesions and who would not be disturbed by residual changes in skin pigmentation or scarring, destructive therapies, such as cryotherapy, curettage and electrodesiccation, photodynamic therapy, and laser therapy, or surgical excision can be offered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with multiple or large lesions, topical pharmacologic therapy with topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> can be offered. For older patients with widespread lesions, radiotherapy with Grenz rays may be a treatment option.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who do not desire intensive treatment, application of keratolytic agents, such as over-the-counter products containing urea or salicylic acid, may be beneficial.</p><p></p><p>The intense inflammatory response that typically accompanies treatment with topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> limits the skin area that can be treated at one time. If treatment of a large area is required, topical retinoids, such as tretinoin or <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a>, may be an alternative, although a longer treatment duration of several months is typically required.</p><p>The response to treatment with topical agents is often unpredictable, and clinicians must remain cognizant that lesions that initially respond well to any treatment can recur. Additional options for the treatment of porokeratosis include emollients and topical keratolytics (eg, salicylic acid). (See <a class="local">'Topical therapies'</a> below.)</p><p>Systemic retinoids are generally restricted to severe cases due to the possibility of systemic adverse effects and the high likelihood for lesion recurrence after the discontinuation of treatment. (See <a class="local">'Surgical and destructive therapies'</a> below and <a class="local">'Systemic therapy'</a> below.)</p><p class="headingAnchor" id="H959933"><span class="h2">Sun protection</span><span class="headingEndMark"> — </span>Due to the possibility for malignant transformation in porokeratosis, patients should be strongly encouraged to engage in protection from ultraviolet radiation, a known risk factor for squamous cell and basal cell carcinoma. (See <a class="local">'Malignant transformation'</a> above.) </p><p>We recommend sun-protective clothing, shelter from the sun, and routine daily use of broad-spectrum sunscreen with a sun protection factor (SPF) of at least 30 on areas of skin that cannot be protected physically. Of note, strict use of sun protection may increase the risk for vitamin D deficiency, especially in patients with phototypes IV to VI. (See  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p class="headingAnchor" id="H553782"><span class="h2">Topical therapies</span></p><p class="headingAnchor" id="H2282840279"><span class="h3">Overview</span><span class="headingEndMark"> — </span>There are no randomized clinical trials assessing topical therapies of porokeratosis, and their use is largely based on indirect evidence from studies on treatment of actinic keratosis (see  <a class="medical medical_review" href="/d/html/5336.html" rel="external">"Treatment of actinic keratosis"</a>). The optimal treatment regimen/duration has not been determined, and the response to treatment is often unpredictable. Combination therapy using several different topical agents or topical agents and destructive therapies may be beneficial.</p><p>Topical therapeutic options for porokeratosis include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>fluorouracil</strong> – Topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> has been used in patients with disseminated superficial actinic porokeratosis (DSAP), disseminated superficial porokeratosis (DSP), porokeratosis of Mibelli, and linear porokeratosis [<a href="#rid48">48,118-121</a>]. Patients are instructed to apply 5% topical fluorouracil cream daily until an intense inflammatory response is attained (typically several weeks). The intense inflammatory response with possible superficial ulceration and postinflammatory hyperpigmentation limits the use of fluorouracil to less esthetically important areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>imiquimod</strong> – Topical <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> has been used in case reports and small case series of patients with porokeratosis of Mibelli, DSAP, linear porokeratosis, and porokeratosis plantaris palmaris et disseminata (PPPD) [<a href="#rid122">122-132</a>]. A systematic review found nine reports (11 patients) of partial to complete resolution of porokeratosis of Mibelli with imiquimod [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1">A reasonable initial course of therapy for <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> is application three to five times per week for a period of four to six weeks [<a href="#rid123">123-125</a>]. Longer or shorter periods of treatment may be needed depending on the treatment response and the occurrence of adverse effects [<a href="#rid126">126,127</a>]. Similar to topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, an intense local inflammatory response is expected during treatment with imiquimod.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical retinoids</strong> – Tretinoin 0.05% cream and 0.1% gel have been beneficial for the treatment of linear porokeratosis [<a href="#rid133">133-135</a>]. <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">Tazarotene</a> and <a class="drug drug_general" data-topicid="9352" href="/d/drug information/9352.html" rel="external">adapalene</a> have also been used in some patients with porokeratosis [<a href="#rid136">136</a>]. Topical retinoids are applied once daily. They are less irritating and induce less inflammation than topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> but require a longer course of treatment (10 to 16 weeks or longer) [<a href="#rid133">133-135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical vitamin D analogs</strong> – Topical vitamin D analogs, such as <a class="drug drug_general" data-topicid="9181" href="/d/drug information/9181.html" rel="external">calcipotriol</a> and tacalcitol, have only been reported to be effective in DSAP, and several months or more of treatment with daily application may be required for improvement [<a href="#rid4">4,137-139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical </strong><strong>diclofenac</strong> – The value of topical <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> 3% gel is unclear. In a series of eight patients with DSAP, only one patient had partial improvement after six months of treatment [<a href="#rid140">140</a>]. In a single case report, topical diclofenac was effective in inducing partial resolution of inflammatory DSAP lesions that persisted despite treatment with systemic retinoids [<a href="#rid57">57</a>]. A small case series suggests that the drug may be effective in reducing disease progression [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical statin-cholesterol</strong> – The combination of 2% <a class="drug drug_general" data-topicid="9923" href="/d/drug information/9923.html" rel="external">simvastatin</a> and 2% cholesterol cream was demonstrated to reduce lesion number, scaling, and erythema compared with emollient in an open-label study [<a href="#rid142">142</a>]. In this study, eight patients with DSAP were treated with simvastatin-cholesterol cream twice daily on one limb and emollients on the other. Simvastatin is believed to inhibit the production of toxic metabolites, while cholesterol is thought to restore the barrier function of the epidermis.</p><p></p><p class="bulletIndent1">In a subsequent, small, randomized trial, 31 participants with DSAP were assigned to treatment with topical <a class="drug drug_general" data-topicid="9575" href="/d/drug information/9575.html" rel="external">lovastatin</a> 2% plus cholesterol 2% cream or lovastatin 2% cream once or twice daily [<a href="#rid143">143</a>]. At 12 weeks, a similar decrease from baseline in disease severity (assessed by the Disseminated Superficial Actinic Porokeratosis General Assessment Severity Index [DSAP-GASI]) was noted in both groups (from 3.08 points [95% CI 2.57-3.60] to 1.54 points [95% CI 1.04-2.05] and from 2.92 points [95% CI 2.40-3.43] to 1.50 points [95% CI 0.99-2.01], respectively).</p><p></p><p class="headingAnchor" id="H3469231525"><span class="h3">Combination topical therapy</span><span class="headingEndMark"> — </span>In the authors' experience, pretreatment of affected skin with a topical retinoid, such as tretinoin or <a class="drug drug_general" data-topicid="9665" href="/d/drug information/9665.html" rel="external">tazarotene</a>, for two to three weeks prior to the use of topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> seems to improve drug penetration and the response to therapy. The relative efficacy of this regimen to treatment with topical fluorouracil or imiquimod alone has not been formally studied in porokeratosis. Other combinations described in a few case reports include <a class="drug drug_general" data-topicid="9352" href="/d/drug information/9352.html" rel="external">adapalene</a> with <a class="drug drug_general" data-topicid="9181" href="/d/drug information/9181.html" rel="external">calcipotriol</a> [<a href="#rid136">136</a>], imiquimod with fluorouracil [<a href="#rid144">144</a>], and topical fluorouracil cream with photodynamic therapy (PDT) [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H972868663"><span class="h3">Adjunctive topical therapies</span><span class="headingEndMark"> — </span>The application of keratolytic agents, such as salicylic acid, may also be beneficial [<a href="#rid146">146</a>]. Successful treatment with salicylic acid in combination with <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> has been reported [<a href="#rid131">131,147</a>]. In two patients with porokeratosis of Mibelli, lesion clearance was achieved with topical <a class="drug drug_general" data-topicid="8838" href="/d/drug information/8838.html" rel="external">cantharidin</a> [<a href="#rid148">148</a>]. </p><p>Topical corticosteroids may provide symptomatic relief but only partial or no improvement of lesions [<a href="#rid122">122</a>]. There is a single report of successful use of topical <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> for linear porokeratosis [<a href="#rid149">149</a>].</p><p>Emollients, especially with keratolytic properties (eg, urea-containing emollients), may be useful in patients with porokeratosis, as they may reduce the rough, dry quality of lesions. </p><p class="headingAnchor" id="H553341"><span class="h2">Surgical and destructive therapies</span><span class="headingEndMark"> — </span>Porokeratosis lesions can be removed or improved with procedures such as cryotherapy, curettage and electrodesiccation, surgical excision, and dermabrasion [<a href="#rid150">150-154</a>]. However, all of these treatments are associated with a high risk of scarring or postinflammatory hyperpigmentation. Alternative approaches include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laser therapy</strong> – Light-based therapies may also be effective. Carbon dioxide laser has been successfully used to treat porokeratosis of Mibelli and linear porokeratosis [<a href="#rid155">155-158</a>]. Improvement in DSAP or DSP has been reported after treatment with a fractional laser, Q-switched ruby laser, frequency-doubled neodymium:yttrium aluminum garnet (Nd:YAG) laser, and erbium:yttrium aluminium garnet (Er:YAG) laser [<a href="#rid159">159-163</a>]. Combination of carbon dioxide laser and conventional methyl aminolevulinate-PDT showed improvement of the condition but no complete resolution of DSAP lesions [<a href="#rid164">164</a>]. (See  <a class="medical medical_review" href="/d/html/13647.html" rel="external">"Photodynamic therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Photodynamic therapy</strong> – Case reports of conventional PDT in DSAP and linear porokeratosis have yielded variable results [<a href="#rid145">145,165-168</a>]. Daylight PDT has led to favorable results in four patients with DSAP [<a href="#rid169">169,170</a>]. (See  <a class="medical medical_review" href="/d/html/13647.html" rel="external">"Photodynamic therapy", section on 'Daylight photodynamic therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation therapy</strong> – In a report of eight patients with DSAP, radiotherapy with Grenz and soft rays resulted in a good response in all patients, with only one recurrence suspected  (<a class="graphic graphic_picture graphicRef120833" href="/d/graphic/120833.html" rel="external">picture 17</a>) [<a href="#rid171">171</a>]. An inflammatory reaction and postinflammatory hyperpigmentation occurred in some cases and resolved spontaneously in several months. Another case series reported 17 patients successfully treated with Grenz rays, with at least 50 percent improvement in all cases [<a href="#rid172">172</a>].</p><p></p><p class="headingAnchor" id="H553623"><span class="h2">Systemic therapy</span><span class="headingEndMark"> — </span>Oral retinoids, including <a class="drug drug_general" data-topicid="9250" href="/d/drug information/9250.html" rel="external">acitretin</a> and <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a>, are infrequently used for the treatment of severe cases of porokeratosis. Retinoids have been reported to be effective in patients with DSAP, linear porokeratosis, porokeratosis of Mibelli, PPPD, and generalized linear lesions [<a href="#rid73">73,173-176</a>]. However, systemic retinoids need to be administered for many months. The degree of improvement is variable; recurrence after treatment discontinuation is likely. Systemic retinoids are teratogenic. Acitretin is contraindicated in female patients of childbearing potential; pregnancy must be avoided for three years after discontinuation.</p><p>In a single case report, a patient with DSAP who received the keratinocyte differentiation factor <a class="drug drug_general" data-topicid="10161" href="/d/drug information/10161.html" rel="external">palifermin</a> for mucositis prophylaxis under chemotherapy for solid tumor treatment showed a marked improvement of DSAP with sustained clearance of the lesions at 12 months follow-up [<a href="#rid177">177</a>].</p><p class="headingAnchor" id="H1959904480"><span class="h1">SKIN CANCER PREVENTION AND SURVEILLANCE</span></p><p class="headingAnchor" id="H939656696"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Although removal of lesions via surgical or destructive methods is an option for the prevention of malignant transformation in lesions of porokeratosis, this is generally not needed or feasible, especially for patients with large or extensive lesions. Factors, such as the estimated risk for malignancy for specific lesion types and the risk for significant cosmetic or functional defects following removal, must be considered. The removal of the lesions with the greatest risk for malignancy (linear porokeratosis or large porokeratosis of Mibelli) often would result in an unacceptable amount of scarring and, possibly, functional impairment.</p><p>Clinical surveillance with regular skin examinations and patient education about the warning signs of skin cancer and sun protection are thus key aspects of the management of patients with major types of porokeratosis. Although malignant transformation in DSAP and DSP is rare compared with porokeratosis of Mibelli and linear porokeratosis, the frequent presence of additional risk factors for cutaneous malignancy (eg, light skin type, history of high sun exposure, immunosuppression) makes close clinical follow-up of these patients worthwhile:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient education </strong>– All patients should be educated about warning signs for malignancy. Patients should be instructed to return for follow-up if changes occur in a previously stable lesion, such as the development of induration, ulceration, nodularity, bleeding, crusting, or rapid growth. Similarly, patients should return for reevaluation if new symptoms develop in lesions (eg, prickling or tingling sensations or pain).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sun protection </strong>–<strong> </strong>The implementation of sun-protective practices is recommended to reduce actinic damage. (See <a class="local">'Sun protection'</a> above and  <a class="medical medical_review" href="/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine follow-up </strong>–<strong> </strong>Patients should be followed annually to monitor for signs and symptoms of malignancy, to screen for changes in health status that might suggest an underlying systemic immunosuppressive disorder, and to reinforce sun protection education. In case of high number or large lesions, more frequent follow-up visits (eg, every six months) should be scheduled. Any lesion that exhibits clinical features suspicious for malignancy (eg, induration, ulceration, bleeding, crusting, rapid growth) should be excised or biopsied for histopathologic examination.</p><p></p><p>If the decision is made to excise or destroy a lesion for prophylactic purposes, doing so in an urgent manner is not necessary, as the period between lesion development and malignancy often spans decades (see <a class="local">'Malignant transformation'</a> above). After removal, clinical follow-up still should be performed yearly to evaluate these patients for the development of new or recurrent lesions.</p><p class="headingAnchor" id="H3504151047"><span class="h2">Immunocompromised patients</span><span class="headingEndMark"> — </span>Although systemic immunosuppression has not been proven to increase the risk for malignant transformation in lesions of porokeratosis [<a href="#rid36">36,101</a>], immunosuppression is a known risk factor for cutaneous malignancy. Thus, skin examinations are often performed more than once yearly for skin cancer surveillance in this population regardless of the presence or absence of porokeratosis. (See  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H312602732"><span class="h2">Chemoprevention</span><span class="headingEndMark"> — </span>Systemic retinoids are occasionally used for the management of patients with severe porokeratosis. Based on indirect evidence from studies on chemoprevention of cutaneous squamous cell carcinoma in solid organ transplant recipients, the risk for malignant transformation may be reduced during active treatment with systemic retinoids [<a href="#rid178">178</a>]. However, this has not been directly studied in porokeratosis, and the long-term impact of retinoid therapy on malignant transformation of these lesions is unknown. </p><p>In a randomized trial, daily use of 1000 mg of <a class="drug drug_general" data-topicid="9696" href="/d/drug information/9696.html" rel="external">nicotinamide</a> for 12 months reduced the number of new basal cell carcinoma and squamous cell carcinoma by 20 and 30 percent, respectively, in patients at high risk of nonmelanoma skin cancer [<a href="#rid179">179</a>]. However, the value of nicotinamide supplementation in the prevention of skin cancer in patients with porokeratosis has not been specifically studied. (See  <a class="medical medical_review" href="/d/html/16339.html" rel="external">"Prevention and management of skin cancer in solid organ transplant recipients", section on 'Chemoprevention for squamous cell carcinoma'</a> and  <a class="medical medical_review" href="/d/html/128194.html" rel="external">"Cutaneous squamous cell carcinoma: Primary and secondary prevention", section on 'Chemoprevention'</a>.)</p><p class="headingAnchor" id="H2269033481"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Without treatment, lesions of porokeratosis usually persist indefinitely [<a href="#rid98">98</a>]. Spontaneous regression is rare [<a href="#rid36">36</a>]. </p><p>Malignant transformation is estimated to occur in 7 to 11 percent of patients with porokeratosis, most often in lesions of linear porokeratosis or giant porokeratosis (a form of porokeratosis of Mibelli). The vast majority of squamous cell carcinomas that develop in lesions of porokeratosis are successfully treated with local therapy. However, several cases of metastatic squamous cell carcinoma arising in the setting of porokeratosis have been reported [<a href="#rid101">101,180-183</a>]. (See  <a class="medical medical_review" href="/d/html/5339.html" rel="external">"Treatment and prognosis of low-risk cutaneous squamous cell carcinoma (cSCC)"</a> and  <a class="medical medical_review" href="/d/html/13713.html" rel="external">"Recognition and management of high-risk (aggressive) cutaneous squamous cell carcinoma"</a>.)</p><p class="headingAnchor" id="H191710"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and classification</strong> – Porokeratosis is a rare, sporadic or inherited disorder of keratinization characterized by the presence of a characteristic ridge-like, keratotic border called a "cornoid lamella"  (<a class="graphic graphic_picture graphicRef62258" href="/d/graphic/62258.html" rel="external">picture 1B</a>). Several clinical variants of porokeratosis, of which the most common are disseminated superficial actinic porokeratosis (DSAP) and porokeratosis of Mibelli, have been described. (See <a class="local">'Introduction'</a> above and <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The defining feature of porokeratosis is the clinical and histopathologic presence of a cornoid lamella, which typically manifests as a thin, keratotic rim at the periphery of a slightly atrophic skin lesion of variable size  (<a class="graphic graphic_picture graphicRef62674 graphicRef62258" href="/d/graphic/62674.html" rel="external">picture 1A-B</a>). Lesions typically begin as small, keratotic papules that spread slowly and centrifugally:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disseminated superficial actinic porokeratosis</strong> – DSAP is the most common form of porokeratosis. Patients are typically adults with a history of chronic sun exposure. Few or many small, porokeratotic macules are usually present on the extensor extremities  (<a class="graphic graphic_picture graphicRef81874 graphicRef62258" href="/d/graphic/81874.html" rel="external">picture 1B, 2B</a>). (See <a class="local">'Disseminated superficial actinic porokeratosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Porokeratosis of Mibelli</strong> – Porokeratosis of Mibelli is the second most common type of porokeratosis. Lesions most commonly begin in childhood but may occur in adults, particularly in the setting of immunosuppression. An annular plaque a few centimeters in diameter with a prominent keratotic ridge is the typical clinical finding  (<a class="graphic graphic_picture graphicRef62674 graphicRef81011 graphicRef109888" href="/d/graphic/62674.html" rel="external">picture 1A, 1C, 1E</a>). (See <a class="local">'Porokeratosis of Mibelli'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of squamous cell carcinoma</strong> – Malignant transformation to squamous cell carcinoma is estimated to occur in 7 to 11 percent of patients with porokeratosis, most often in lesions of linear porokeratosis or giant porokeratosis (a form of porokeratosis of Mibelli). (See <a class="local">'Malignant transformation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Clinical examination is usually sufficient for the diagnosis of porokeratosis. Skin biopsy may be useful in the setting of atypical lesions or lesions that are suspicious for malignant transformation. Biopsy of the periphery of the lesion characteristically demonstrates a cornoid lamella, consisting of a narrow column of parakeratotic cells  (<a class="graphic graphic_picture graphicRef61211" href="/d/graphic/61211.html" rel="external">picture 7A</a>). (See <a class="local">'Diagnosis'</a> above and <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Education about sun protection and clinical surveillance for malignant transformation are sufficient for the management of most patients with porokeratosis. However, patients with symptomatic or cosmetically distressing lesions may desire treatment (see <a class="local">'General approach'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with few small lesions</strong> – For patients with a few small lesions who desire rapid treatment for symptom relief or cosmetic purposes, we suggest treatment with destructive therapies (eg, cryotherapy, curettage and electrodesiccation, laser therapy) or surgical excision (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment-related pigmentation changes or scarring may occur. (See <a class="local">'Surgical and destructive therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with large or multiple lesions</strong> – For patients with large or multiple lesions that are not amenable to surgical or destructive therapy, we suggest treatment with topical therapies rather than systemic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> may be used for the treatment of localized areas. Topical retinoids are a less irritating therapeutic option and, thus, suitable for use on larger areas but may require a longer course of therapy. (See <a class="local">'Topical therapies'</a> above.)</p><p></p><p class="bulletIndent2">Sequential therapy with topical retinoids for two to three weeks followed by a course of topical <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> or <a class="drug drug_general" data-topicid="8638" href="/d/drug information/8638.html" rel="external">imiquimod</a> may enhance drug penetration and response to treatment (see <a class="local">'Combination topical therapy'</a> above). Treatment with systemic retinoids is usually reserved for severe cases. Relapse is likely after treatment cessation. (See <a class="local">'Systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin cancer prevention and surveillance</strong> – Clinical surveillance with annual skin examinations and patient education about the warning signs of skin cancer and sun protection are key aspects of the management of patients with major types of porokeratosis. (See <a class="local">'Skin cancer prevention and surveillance'</a> above.)</p><p></p><p class="headingAnchor" id="H2646141594"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Linda V Spencer, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kanitakis J. Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features. Eur J Dermatol 2014; 24:533.</a></li><li class="breakAll">Williams GM, Fillman EP. Porokeratosis. In: StatPearls, StatPearls Publishing, Treasure Island (FL) 2018.</li><li><a class="nounderline abstract_t">Leow YH, Soon YH, Tham SN. A report of 31 cases of porokeratosis at the National Skin Centre. Ann Acad Med Singapore 1996; 25:837.</a></li><li><a class="nounderline abstract_t">Niimi Y, Kawana S. Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl. Eur J Dermatol 2009; 19:25.</a></li><li><a class="nounderline abstract_t">Tan LS, Chong WS. Porokeratosis in Singapore: an Asian perspective. Australas J Dermatol 2012; 53:e40.</a></li><li><a class="nounderline abstract_t">Gu CY, Zhang CF, Chen LJ, et al. Clinical analysis and etiology of porokeratosis. Exp Ther Med 2014; 8:737.</a></li><li><a class="nounderline abstract_t">Gracia-Cazaña T, Vera-Álvarez J, García-Patos V, Gilaberte Y. Imiquimod and Photodynamic Therapy Are Useful in the Treatment of Porokeratosis in Children with Bone Marrow Transplantation. Pediatr Dermatol 2015; 32:e291.</a></li><li><a class="nounderline abstract_t">Murase J, Gilliam AC. Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis. J Am Acad Dermatol 2010; 63:886.</a></li><li><a class="nounderline abstract_t">Xia JH, Yang YF, Deng H, et al. Identification of a locus for disseminated superficial actinic porokeratosis at chromosome 12q23.2-24.1. J Invest Dermatol 2000; 114:1071.</a></li><li><a class="nounderline abstract_t">Xia K, Deng H, Xia JH, et al. A novel locus (DSAP2) for disseminated superficial actinic porokeratosis maps to chromosome 15q25.1-26.1. Br J Dermatol 2002; 147:650.</a></li><li><a class="nounderline abstract_t">Liu P, Zhang S, Yao Q, et al. Identification of a genetic locus for autosomal dominant disseminated superficial actinic porokeratosis on chromosome 1p31.3-p31.1. Hum Genet 2008; 123:507.</a></li><li><a class="nounderline abstract_t">Luan J, Niu Z, Zhang J, et al. A novel locus for disseminated superficial actinic porokeratosis maps to chromosome 16q24.1-24.3. Hum Genet 2011; 129:329.</a></li><li><a class="nounderline abstract_t">Cui H, Li L, Wang W, et al. Exome sequencing identifies SLC17A9 pathogenic gene in two Chinese pedigrees with disseminated superficial actinic porokeratosis. J Med Genet 2014; 51:699.</a></li><li><a class="nounderline abstract_t">Leng Y, Yan L, Feng H, et al. Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis. J Dermatol 2018; 45:862.</a></li><li><a class="nounderline abstract_t">Zhang SQ, Jiang T, Li M, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet 2012; 44:1156.</a></li><li><a class="nounderline abstract_t">Zhou Y, Liu J, Fu X, et al. Identification of three novel frameshift mutations of the MVK gene in four Chinese families with disseminated superficial actinic porokeratosis. Br J Dermatol 2013; 169:193.</a></li><li><a class="nounderline abstract_t">Li M, Li Z, Wang J, et al. Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis. J Eur Acad Dermatol Venereol 2016; 30:1512.</a></li><li><a class="nounderline abstract_t">Zhang Z, Li C, Wu F, et al. Genomic variations of the mevalonate pathway in porokeratosis. Elife 2015; 4:e06322.</a></li><li><a class="nounderline abstract_t">Moir RD, Spann TP. The structure and function of nuclear lamins: implications for disease. Cell Mol Life Sci 2001; 58:1748.</a></li><li><a class="nounderline abstract_t">Jin R, Luo X, Luan K, et al. Disorder of the mevalonate pathway inhibits calcium-induced differentiation of keratinocytes. Mol Med Rep 2017; 16:4811.</a></li><li><a class="nounderline abstract_t">Wei S, Yang S, Lin D, et al. A novel locus for disseminated superficial porokeratosis maps to chromosome 18p11.3. J Invest Dermatol 2004; 123:872.</a></li><li><a class="nounderline abstract_t">Wei S, Zhang TD, Zhou Y, et al. Fine mapping of the disseminated superficial porokeratosis locus to a 2.7 Mb region at 18p11.3. Clin Exp Dermatol 2010; 35:664.</a></li><li><a class="nounderline abstract_t">Wei SC, Yang S, Li M, et al. Identification of a locus for porokeratosis palmaris et plantaris disseminata to a 6.9-cM region at chromosome 12q24.1-24.2. Br J Dermatol 2003; 149:261.</a></li><li><a class="nounderline abstract_t">Happle R. Mibelli revisited: a case of type 2 segmental porokeratosis from 1893. J Am Acad Dermatol 2010; 62:136.</a></li><li><a class="nounderline abstract_t">Atzmony L, Khan HM, Lim YH, et al. Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis. JAMA Dermatol 2019; 155:548.</a></li><li><a class="nounderline abstract_t">Chernosky ME, Freeman RG. Disseminated superficial actinic porokeratosis (DSAP). Arch Dermatol 1967; 96:611.</a></li><li><a class="nounderline abstract_t">Neumann RA, Knobler RM, Jurecka W, Gebhart W. Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions. J Am Acad Dermatol 1989; 21:1182.</a></li><li><a class="nounderline abstract_t">Shin EJ, Gwak MJ, Jeong KH, Lee MH. Disseminated Superficial Actinic Porokeratosis in a Vitiligo Patient Undergoing Treatment with Long-Term Narrowband Ultraviolet B. Ann Dermatol 2018; 30:249.</a></li><li><a class="nounderline abstract_t">Zhao MJ, Abdul-Fattah B, Qu XY, et al. Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature. Medicine (Baltimore) 2016; 95:e5043.</a></li><li><a class="nounderline abstract_t">Schwarz T, Seiser A, Gschnait F. Disseminated superficial "actinic" porokeratosis. J Am Acad Dermatol 1984; 11:724.</a></li><li><a class="nounderline abstract_t">Raychaudhuri SP, Smoller BR. Porokeratosis in immunosuppressed and nonimmunosuppressed patients. Int J Dermatol 1992; 31:781.</a></li><li><a class="nounderline abstract_t">Rodríguez EA, Jakubowicz S, Chinchilla DA, et al. Porokeratosis of Mibelli and HIV-infection. Int J Dermatol 1996; 35:402.</a></li><li><a class="nounderline abstract_t">Herranz P, Pizarro A, De Lucas R, et al. High incidence of porokeratosis in renal transplant recipients. Br J Dermatol 1997; 136:176.</a></li><li><a class="nounderline abstract_t">Alexis AF, Busam K, Myskowski PL. Porokeratosis of Mibelli following bone marrow transplantation. Int J Dermatol 2006; 45:361.</a></li><li><a class="nounderline abstract_t">Komorowski RA, Clowry LJ. Porokeratosis of mibelli in transplant recipients. Am J Clin Pathol 1989; 91:71.</a></li><li><a class="nounderline abstract_t">Kanitakis J, Euvrard S, Faure M, Claudy A. Porokeratosis and immunosuppression. Eur J Dermatol 1998; 8:459.</a></li><li><a class="nounderline abstract_t">Rothman IL, Wirth PB, Klaus MV. Porokeratosis of Mibelli following heart transplant. Int J Dermatol 1992; 31:52.</a></li><li><a class="nounderline abstract_t">Bednarek R, Ezra N, Toubin Y, et al. Eruptive disseminated porokeratosis associated with corticosteroid-induced immunosuppression. Clin Exp Dermatol 2015; 40:753.</a></li><li><a class="nounderline abstract_t">Sertznig P, von Felbert V, Megahed M. Porokeratosis: present concepts. J Eur Acad Dermatol Venereol 2012; 26:404.</a></li><li><a class="nounderline abstract_t">Shoimer I, Robertson LH, Storwick G, Haber RM. Eruptive disseminated porokeratosis: a new classification system. J Am Acad Dermatol 2014; 71:398.</a></li><li><a class="nounderline abstract_t">Kanitakis J, Misery L, Nicolas JF, et al. Disseminated superficial porokeratosis in a patient with AIDS. Br J Dermatol 1994; 131:284.</a></li><li><a class="nounderline abstract_t">Gilead L, Guberman D, Zlotogorski A, et al. Immunosuppression-induced porokeratosis of Mibelli: Complete regression of lesions upon cessation of immunosuppressive therapy. J Eur Acad Dermatol Venereol 1995; 5:170.</a></li><li><a class="nounderline abstract_t">Tsambaos D, Spiliopoulos T. Disseminated superficial porokeratosis: complete remission subsequent to discontinuation of immunosuppression. J Am Acad Dermatol 1993; 28:651.</a></li><li><a class="nounderline abstract_t">Yazkan F, Turk BG, Dereli T, Kazandi AC. Porokeratosis of Mibelli induced by topical corticosteroid. J Cutan Pathol 2006; 33:516.</a></li><li><a class="nounderline abstract_t">James AJ, Clarke LE, Elenitsas R, Katz K. Segmental porokeratosis after radiation therapy for follicular lymphoma. J Am Acad Dermatol 2008; 58:S49.</a></li><li><a class="nounderline abstract_t">Romaní J, Pujol RM, Casanova JM, de Moragas JM. Disseminated superficial porokeratosis developing after electron-beam total skin irradiation for mycosis fungoides. Clin Exp Dermatol 1996; 21:310.</a></li><li><a class="nounderline abstract_t">Nova MP, Goldberg LJ, Mattison T, Halperin A. Porokeratosis arising in a burn scar. J Am Acad Dermatol 1991; 25:354.</a></li><li><a class="nounderline abstract_t">Dippel E, Haas N, Czarnetzki BM. Porokeratosis of Mibelli associated with active chronic hepatitis and vitiligo. Acta Derm Venereol 1994; 74:463.</a></li><li><a class="nounderline abstract_t">Hunt SJ, Sharra WG, Abell E. Linear and punctate porokeratosis associated with end-stage liver disease. J Am Acad Dermatol 1991; 25:937.</a></li><li><a class="nounderline abstract_t">Cannavó SP, Borgia F, Adamo B, Guarneri B. Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? J Am Acad Dermatol 2008; 58:657.</a></li><li><a class="nounderline abstract_t">Kono T, Kobayashi H, Ishii M, et al. Synchronous development of disseminated superficial porokeratosis and hepatitis C virus-related hepatocellular carcinoma. J Am Acad Dermatol 2000; 43:966.</a></li><li><a class="nounderline abstract_t">Morton CA, Shuttleworth D, Douglas WS. Porokeratosis and Crohn's disease. J Am Acad Dermatol 1995; 32:894.</a></li><li><a class="nounderline abstract_t">Lu JD, Mufti A, Sachdeva M, et al. Drugs associated with development of porokeratosis: A systematic review. Dermatol Ther 2021; 34:e14560.</a></li><li><a class="nounderline abstract_t">Magalhães C, Costa M, Campainha S, et al. Histopathologic findings of drug-induced eruptive porokeratosis under nivolumab therapy. J Cutan Pathol 2023; 50:298.</a></li><li><a class="nounderline abstract_t">Romagnuolo M, Riva D, Alberti Violetti S, et al. Disseminated superficial actinic porokeratosis following hydroxyurea treatment: A case report. Australas J Dermatol 2023; 64:e72.</a></li><li><a class="nounderline abstract_t">Sawyer R, Picou KA. Facial presentation of disseminated superficial actinic porokeratosis. Ear Nose Throat J 1989; 68:57.</a></li><li><a class="nounderline abstract_t">Shimizu S, Takashima Y, Hotta M, et al. Inflammatory disseminated superficial porokeratosis successfully controlled with a combination of topical diclofenac gel and systemic etretinate. J Eur Acad Dermatol Venereol 2018; 32:e201.</a></li><li><a class="nounderline abstract_t">Bencini PL, Tarantino A, Grimalt R, et al. Porokeratosis and immunosuppression. Br J Dermatol 1995; 132:74.</a></li><li><a class="nounderline abstract_t">Chun SI, Lee JS, Kim NS, Park KD. Disseminated epidermolytic acanthoma with disseminated superficial porokeratosis and verruca vulgaris in an immunosuppressed patient. J Dermatol 1995; 22:690.</a></li><li><a class="nounderline abstract_t">Rio B, Magana C, Le Tourneau A, et al. Disseminated superficial porokeratosis after autologous bone marrow transplantation. Bone Marrow Transplant 1997; 19:77.</a></li><li><a class="nounderline abstract_t">Knoell KA, Patterson JW, Wilson BB. Sudden onset of disseminated porokeratosis of Mibelli in a renal transplant patient. J Am Acad Dermatol 1999; 41:830.</a></li><li><a class="nounderline abstract_t">Bozdağ KE, Biçakçi H, Ermete M. Giant porokeratosis. Int J Dermatol 2004; 43:518.</a></li><li><a class="nounderline abstract_t">Raychaudhury T, Valsamma DP. Giant porokeratosis. Indian J Dermatol Venereol Leprol 2011; 77:601.</a></li><li><a class="nounderline abstract_t">Koley S, Sarkar J, Choudhary S, et al. Different morphological variants of hypertrophic porokeratosis and disseminated lesions of porokeratosis of Mibelli: a rare co-existence. Indian J Dermatol Venereol Leprol 2011; 77:199.</a></li><li><a class="nounderline abstract_t">Thomas C, Ogboli MI, Carr RA, Charles-Holmes R. Hypertrophic perianal porokeratosis in association with superficial actinic porokeratosis of the leg. Clin Exp Dermatol 2003; 28:676.</a></li><li><a class="nounderline abstract_t">Robinson JB, Im DD, Jockle G, Rosenshein NB. Vulvar porokeratosis: case report and review of the literature. Int J Gynecol Pathol 1999; 18:169.</a></li><li><a class="nounderline abstract_t">Neri I, Marzaduri S, Passarini B, Patrizi A. Genital porokeratosis of Mibelli. Genitourin Med 1995; 71:410.</a></li><li><a class="nounderline abstract_t">Rajesh G, Devan P, Keerthi S, Karthikeyan K. Acral porokeratosis associated with anonychia. Indian J Dermatol Venereol Leprol 2018; 84:81.</a></li><li><a class="nounderline abstract_t">Friedman B, Golubets K, Ho J, Patton T. Linear porokeratosis associated with multiple squamous cell carcinomas. Cutis 2017; 100:E11.</a></li><li><a class="nounderline abstract_t">Sommerlad M, Lock A, Moir G, et al. Linear porokeratosis with multiple squamous cell carcinomas successfully treated by electrochemotherapy. Br J Dermatol 2016; 175:1342.</a></li><li><a class="nounderline abstract_t">Guenova E, Hoetzenecker W, Metzler G, et al. Multicentric Bowen disease in linear porokeratosis. Eur J Dermatol 2007; 17:439.</a></li><li><a class="nounderline abstract_t">Happle R. Cancer proneness of linear porokeratosis may be explained by allelic loss. Dermatology 1997; 195:20.</a></li><li><a class="nounderline abstract_t">Hartman R, Mandal R, Sanchez M, Stein JA. Porokeratosis plantaris, palmaris, et disseminata. Dermatol Online J 2010; 16:22.</a></li><li><a class="nounderline abstract_t">Marschalkó M, Somlai B. Porokeratosis plantaris, palmaris, et disseminata. Arch Dermatol 1986; 122:890.</a></li><li><a class="nounderline abstract_t">Irisawa R, Yamazaki M, Yamamoto T, Tsuboi R. A case of porokeratosis plantaris palmaris et disseminata and literature review. Dermatol Online J 2012; 18:5.</a></li><li><a class="nounderline abstract_t">Shaw JC, White CR Jr. Porokeratosis plantaris palmaris et disseminata. J Am Acad Dermatol 1984; 11:454.</a></li><li><a class="nounderline abstract_t">Patrizi A, Passarini B, Minghetti G, Masina M. Porokeratosis palmaris et plantaris disseminata: an unusual clinical presentation. J Am Acad Dermatol 1989; 21:415.</a></li><li><a class="nounderline abstract_t">Lestringant GG, Berge T. Porokeratosis punctata palmaris et plantaris. A new entity? Arch Dermatol 1989; 125:816.</a></li><li><a class="nounderline abstract_t">Sakas EL, Gentry RH. Porokeratosis punctata palmaris et plantaris (punctate porokeratosis). Case report and literature review. J Am Acad Dermatol 1985; 13:908.</a></li><li><a class="nounderline abstract_t">Tallon B, Blumental G, Bhawan J. Porokeratosis ptychotropica: a lesser-known variant. Clin Exp Dermatol 2009; 34:e895.</a></li><li><a class="nounderline abstract_t">McGuigan K, Shurman D, Campanelli C, Lee JB. Porokeratosis ptychotropica: a clinically distinct variant of porokeratosis. J Am Acad Dermatol 2009; 60:501.</a></li><li><a class="nounderline abstract_t">Yeo J, Winhoven S, Tallon B. Porokeratosis ptychotropica: a rare and evolving variant of porokeratosis. J Cutan Pathol 2013; 40:1042.</a></li><li><a class="nounderline abstract_t">D'souza P, Dhali TK, Arora S, et al. Porokeratosis ptychotropica: a rare variant of porokeratosis. Dermatol Online J 2014; 20.</a></li><li><a class="nounderline abstract_t">Wanat KA, Gormley RH, Bennett DD, Kovarik CL. Genitogluteal porokeratosis involving the scrotum: an unusual presentation of an uncommon disease. J Cutan Pathol 2012; 39:72.</a></li><li><a class="nounderline abstract_t">Joshi R, Minni K. Genitogluteal porokeratosis: a clinical review. Clin Cosmet Investig Dermatol 2018; 11:219.</a></li><li><a class="nounderline abstract_t">Joshi R, Jadhav Y. Penoscrotal porokeratosis: A distinct entity. Indian Dermatol Online J 2015; 6:339.</a></li><li><a class="nounderline abstract_t">Liang C, Batra P, Patel R, Kamino H. Genital porokeratosis. Dermatol Online J 2009; 15:23.</a></li><li><a class="nounderline abstract_t">Lee Y, Choi EH. Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae. J Dermatol 2011; 38:1072.</a></li><li><a class="nounderline abstract_t">Rocha-Sousa VL, Costa JB, de Aquino Paulo-Filho T, et al. Follicular porokeratosis on the face. Am J Dermatopathol 2011; 33:636.</a></li><li><a class="nounderline abstract_t">Wang NS, Gruson LM, Kamino H. Facial follicular porokeratosis: a case report. Am J Dermatopathol 2010; 32:720.</a></li><li><a class="nounderline abstract_t">Kim J, Wood BA, Harvey NT. Follicular porokeratosis of the nose: two further cases of an emerging variant of porokeratosis. Pathology 2015; 47:482.</a></li><li><a class="nounderline abstract_t">Kanekura T, Yoshii N. Eruptive pruritic papular porokeratosis: a pruritic variant of porokeratosis. J Dermatol 2006; 33:813.</a></li><li><a class="nounderline abstract_t">Kanzaki T, Miwa N, Kobayashi T, Ogawa S. Eruptive pruritic papular porokeratosis. J Dermatol 1992; 19:109.</a></li><li><a class="nounderline abstract_t">Stork J, Kodetová D. Disseminated superficial porokeratosis: an eruptive pruritic papular variant. Dermatology 1997; 195:304.</a></li><li><a class="nounderline abstract_t">Kaushik A, Handa S, Chatterjee D, et al. Disseminated filiform hyperkeratosis - a variant of porokeratosis? J Eur Acad Dermatol Venereol 2018; 32:e419.</a></li><li><a class="nounderline abstract_t">Flanagan N, Boyadjiev SA, Harper J, et al. Familial craniosynostosis, anal anomalies, and porokeratosis: CAP syndrome. J Med Genet 1998; 35:763.</a></li><li><a class="nounderline abstract_t">Mendoza-Londono R, Lammer E, Watson R, et al. Characterization of a new syndrome that associates craniosynostosis, delayed fontanel closure, parietal foramina, imperforate anus, and skin eruption: CDAGS. Am J Hum Genet 2005; 77:161.</a></li><li><a class="nounderline abstract_t">Sasson M, Krain AD. Porokeratosis and cutaneous malignancy. A review. Dermatol Surg 1996; 22:339.</a></li><li><a class="nounderline abstract_t">Maubec E, Duvillard P, Margulis A, et al. Common skin cancers in porokeratosis. Br J Dermatol 2005; 152:1389.</a></li><li><a class="nounderline abstract_t">Goerttler EA, Jung EG. Porokeratosis [correction of Parakeratosis] Mibelli and skin carcinoma: a critical review. Humangenetik 1975; 26:291.</a></li><li><a class="nounderline abstract_t">Silver SG, Crawford RI. Fatal squamous cell carcinoma arising from transplant-associated porokeratosis. J Am Acad Dermatol 2003; 49:931.</a></li><li><a class="nounderline abstract_t">Otsuka F, Umebayashi Y, Watanabe S, et al. Porokeratosis large skin lesions are susceptible to skin cancer development: histological and cytological explanation for the susceptibility. J Cancer Res Clin Oncol 1993; 119:395.</a></li><li><a class="nounderline abstract_t">Lin JH, Hsu MM, Sheu HM, Lee JY. Coexistence of three variants of porokeratosis with multiple squamous cell carcinomas arising from lesions of giant hyperkeratotic porokeratosis. J Eur Acad Dermatol Venereol 2006; 20:621.</a></li><li><a class="nounderline abstract_t">Zaar O, Polesie S, Navarrete-Dechent C, et al. Dermoscopy of porokeratosis: results from a multicentre study of the International Dermoscopy Society. J Eur Acad Dermatol Venereol 2021; 35:2091.</a></li><li><a class="nounderline abstract_t">Uenishi T, Teramura K, Kitamura M, et al. Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits. J Dermatol 2010; 37:475.</a></li><li><a class="nounderline abstract_t">Carlesimo M, Rossi A, Fidanza L, et al. Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits. Case Rep Dermatol 2009; 1:35.</a></li><li><a class="nounderline abstract_t">Tan TS, Tallon B. Pigmented Porokeratosis. A Further Variant? Am J Dermatopathol 2016; 38:218.</a></li><li><a class="nounderline abstract_t">Wade TR, Ackerman AB. Cornoid lamellation. A histologic reaction pattern. Am J Dermatopathol 1980; 2:5.</a></li><li><a class="nounderline abstract_t">Zaballos P, Puig S, Malvehy J. Dermoscopy of disseminated superficial actinic porokeratosis. Arch Dermatol 2004; 140:1410.</a></li><li><a class="nounderline abstract_t">Panasiti V, Rossi M, Curzio M, et al. Disseminated superficial actinic porokeratosis diagnosed by dermoscopy. Int J Dermatol 2008; 47:308.</a></li><li><a class="nounderline abstract_t">Uhara H, Kamijo F, Okuyama R, Saida T. Open pores with plugs in porokeratosis clearly visualized with the dermoscopic furrow ink test: report of 3 cases. Arch Dermatol 2011; 147:866.</a></li><li><a class="nounderline abstract_t">Oiso N, Kawada A. Dermoscopic features in disseminated superficial actinic porokeratosis. Eur J Dermatol 2011; 21:439.</a></li><li><a class="nounderline abstract_t">Pizzichetta MA, Canzonieri V, Massone C, Soyer HP. Clinical and dermoscopic features of porokeratosis of Mibelli. Arch Dermatol 2009; 145:91.</a></li><li><a class="nounderline abstract_t">Urbina F, Pérez A, Requena L, Rütten A. Circumscribed palmar or plantar hypokeratosis 10 years after the first description: what is known and the issues under discussion. Actas Dermosifiliogr 2014; 105:574.</a></li><li><a class="nounderline abstract_t">Elfatoiki FZ, Soussi W, Chiheb S, et al. Cutaneous sarcoidosis simulating porokeratosis of Mibelli. Pan Afr Med J 2015; 20:195.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Hilty N, Kempf W. Porokeratotic adnexal ostial naevus: review on the entity and therapeutic approach. J Eur Acad Dermatol Venereol 2015; 29:2032.</a></li><li><a class="nounderline abstract_t">Goddard DS, Rogers M, Frieden IJ, et al. Widespread porokeratotic adnexal ostial nevus: clinical features and proposal of a new name unifying porokeratotic eccrine ostial and dermal duct nevus and porokeratotic eccrine and hair follicle nevus. J Am Acad Dermatol 2009; 61:1060.e1.</a></li><li><a class="nounderline abstract_t">Shelley WB, Shelley ED. Disseminated superficial porokeratosis: rapid therapeutic response to 5-fluorouracil. Cutis 1983; 32:139.</a></li><li><a class="nounderline abstract_t">Gonçalves JC. Fluorouracil ointment treatment of porokeratosis of Mibelli. Arch Dermatol 1973; 108:131.</a></li><li><a class="nounderline abstract_t">McDonald SG, Peterka ES. Porokeratosis (Mibelli): treatment with topical 5-fluorouracil. J Am Acad Dermatol 1983; 8:107.</a></li><li><a class="nounderline abstract_t">Balato N, Di Nardo G, Boccia L, Nappa P. [Linear Mibelli's porokeratosis. Treatment with topical 5-fluorouracil]. G Ital Dermatol Venereol 1986; 121:147.</a></li><li><a class="nounderline abstract_t">Weidner T, Illing T, Miguel D, Elsner P. Treatment of Porokeratosis: A Systematic Review. Am J Clin Dermatol 2017; 18:435.</a></li><li><a class="nounderline abstract_t">Harrison S, Sinclair R. Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream. Australas J Dermatol 2003; 44:281.</a></li><li><a class="nounderline abstract_t">Montes-De-Oca-Sánchez G, Tirado-Sánchez A, García-Ramírez V. Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod. J Dermatolog Treat 2006; 17:319.</a></li><li><a class="nounderline abstract_t">Arun B, Pearson J, Chalmers R. Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. Clin Exp Dermatol 2011; 36:509.</a></li><li><a class="nounderline abstract_t">Jain S. Successful treatment of porokeratosis of Mibelli with imiquimod 5% cream. Clin Exp Dermatol 2006; 31:302.</a></li><li><a class="nounderline abstract_t">Ahn SJ, Lee HJ, Chang SE, et al. Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream. J Dermatol 2007; 34:146.</a></li><li><a class="nounderline abstract_t">Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2002; 146:338.</a></li><li><a class="nounderline abstract_t">Jensen JM, Egberts F, Proksch E, Hauschild A. Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy. Acta Derm Venereol 2005; 85:550.</a></li><li><a class="nounderline abstract_t">Esser AC, Pittelkow MR, Randle HW. Human papillomavirus isolated from transplant-associated porokeratoses of mibelli responsive to topical 5% imiquimod cream. Dermatol Surg 2006; 32:858.</a></li><li><a class="nounderline abstract_t">Erbagci Z, Tuncel AA, Erbagci I. Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases. J Drugs Dermatol 2006; 5:668.</a></li><li><a class="nounderline abstract_t">Gajic B, Tang K, Whitfeld M. Porokeratosis of Mibelli: Involution and resolution with 5% imiquimod cream. Australas J Dermatol 2011; 52:301.</a></li><li><a class="nounderline abstract_t">Grover C, Goel A, Nanda S, et al. A case of extensive linear porokeratosis with evaluation of topical tretinoin versus 5-flourouracil as treatment modalities. J Dermatol 2005; 32:1000.</a></li><li><a class="nounderline abstract_t">Dervis E, Demirkesen C. Generalized linear porokeratosis. Int J Dermatol 2006; 45:1077.</a></li><li><a class="nounderline abstract_t">Agrawal SK, Gandhi V, Madan V, Bhattacharya SN. Topical tretinoin in Indian male with zosteriform porokeratosis. Int J Dermatol 2003; 42:919.</a></li><li><a class="nounderline abstract_t">Nakamura Y, Yamaguchi M, Nakamura A, Muto M. Calcipotriol and adapalene therapy for disseminated superficial actinic porokeratosis. Indian J Dermatol Venereol Leprol 2014; 80:373.</a></li><li><a class="nounderline abstract_t">Böhm M, Luger TA, Bonsmann G. Disseminated superficial actinic porokeratosis: treatment with topical tacalcitol. J Am Acad Dermatol 1999; 40:479.</a></li><li><a class="nounderline abstract_t">Abe M, Yokoyama Y, Ishikawa O. Successful treatment of disseminated superficial actinic porokeratosis with tacalcitol lotion. J Dermatol 2010; 37:913.</a></li><li><a class="nounderline abstract_t">Harrison PV, Stollery N. Disseminated superficial actinic porokeratosis responding to calcipotriol. Clin Exp Dermatol 1994; 19:95.</a></li><li><a class="nounderline abstract_t">Vlachou C, Kanelleas AI, Martin-Clavijo A, Berth-Jones J. Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series. J Eur Acad Dermatol Venereol 2008; 22:1343.</a></li><li><a class="nounderline abstract_t">Marks S, Varma R, Cantrell W, et al. Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:42.</a></li><li><a class="nounderline abstract_t">Byth LA, Byth J. Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: An open-label, split-body clinical trial. Australas J Dermatol 2021; 62:310.</a></li><li><a class="nounderline abstract_t">Santa Lucia G, Snyder A, Lateef A, et al. Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis: A Randomized Clinical Trial. JAMA Dermatol 2023; 159:488.</a></li><li><a class="nounderline abstract_t">Venkatarajan S, LeLeux TM, Yang D, et al. Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil. Dermatol Online J 2010; 16:10.</a></li><li><a class="nounderline abstract_t">Levitt J, Emer JJ, Emanuel PO. Treatment of porokeratosis of mibelli with combined use of photodynamic therapy and Fluorouracil cream. Arch Dermatol 2010; 146:371.</a></li><li><a class="nounderline abstract_t">Jih MH. Porokeratosis plantaris, palmaris, et disseminata. Dermatol Online J 2003; 9:34.</a></li><li><a class="nounderline abstract_t">Danby W. Treatment of porokeratosis with fluorouracil and salicylic acid under occlusion. Dermatol Online J 2003; 9:33.</a></li><li><a class="nounderline abstract_t">Levitt JO, Keeley BR, Phelps RG. Treatment of porokeratosis of Mibelli with cantharidin. J Am Acad Dermatol 2013; 69:e254.</a></li><li><a class="nounderline abstract_t">Parks AC, Conner KJ, Armstrong CA. Long-term clearance of linear porokeratosis with tacrolimus, 0.1%, ointment. JAMA Dermatol 2014; 150:194.</a></li><li><a class="nounderline abstract_t">Bhushan M, Craven NM, Beck MH, Chalmers RJ. Linear porokeratosis of mibelli: successful treatment with cryotherapy. Br J Dermatol 1999; 141:389.</a></li><li><a class="nounderline abstract_t">Chowdhury MM, Inaloz HS, Holt PJ. A scaly macule on the bridge of the nose of a 15-year-old boy. Pediatr Dermatol 2000; 17:149.</a></li><li><a class="nounderline abstract_t">Carranza DC, Haley JC, Chiu M. Facial porokeratosis. Skinmed 2008; 7:51.</a></li><li><a class="nounderline abstract_t">Cohen PR, Held JL, Katz BE. Linear porokeratosis: successful treatment with diamond fraise dermabrasion. J Am Acad Dermatol 1990; 23:975.</a></li><li><a class="nounderline abstract_t">Spencer JM, Katz BE. Successful treatment of porokeratosis of Mibelli with diamond fraise dermabrasion. Arch Dermatol 1992; 128:1187.</a></li><li><a class="nounderline abstract_t">Barnett JH. Linear porokeratosis: treatment with the carbon dioxide laser. J Am Acad Dermatol 1986; 14:902.</a></li><li><a class="nounderline abstract_t">Rabbin PE, Baldwin HE. Treatment of porokeratosis of Mibelli with CO2 laser vaporization versus surgical excision with split-thickness skin graft. A comparison. J Dermatol Surg Oncol 1993; 19:199.</a></li><li><a class="nounderline abstract_t">Hunziker T, Bayard W. Carbon dioxide laser in the treatment of porokeratosis. J Am Acad Dermatol 1987; 16:625.</a></li><li><a class="nounderline abstract_t">McCullough TL, Lesher JL Jr. Porokeratosis of Mibelli: rapid recurrence of a large lesion after carbon dioxide laser treatment. Pediatr Dermatol 1994; 11:267.</a></li><li><a class="nounderline abstract_t">Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis. Arch Dermatol 2007; 143:1450.</a></li><li><a class="nounderline abstract_t">Itoh M, Nakagawa H. Successful treatment of disseminated superficial actinic porokeratosis with Q-switched ruby laser. J Dermatol 2007; 34:816.</a></li><li><a class="nounderline abstract_t">Lolis MS, Marmur ES. Treatment of disseminated superficial actinic porokeratosis (DSAP) with the Q-switched ruby laser. J Cosmet Laser Ther 2008; 10:124.</a></li><li><a class="nounderline abstract_t">Liu HT. Treatment of lichen amyloidosis (LA) and disseminated superficial porokeratosis (DSP) with frequency-doubled Q-switched Nd:YAG laser. Dermatol Surg 2000; 26:958.</a></li><li><a class="nounderline abstract_t">Rosenblum J, Roenigk HH Jr. Erbium laser for the treatment of disseminated superficial actinic porokeratosis: a case report. Dermatol Surg 2013; 39:1543.</a></li><li><a class="nounderline abstract_t">Kim HS, Baek JH, Park YM, et al. Photodynamic Therapy Combined with CO(2) Laser Vaporization on Disseminated Superficial Actinic Porokeratosis: A Report of 2 Cases on the Face. Ann Dermatol 2011; 23:S211.</a></li><li><a class="nounderline abstract_t">Nayeemuddin FA, Wong M, Yell J, Rhodes LE. Topical photodynamic therapy in disseminated superficial actinic porokeratosis. Clin Exp Dermatol 2002; 27:703.</a></li><li><a class="nounderline abstract_t">Fernández-Guarino M, Harto A, Pérez-Garcia B, et al. Photodynamic therapy in disseminated superficial actinic porokeratosis. J Eur Acad Dermatol Venereol 2009; 23:176.</a></li><li><a class="nounderline abstract_t">Cavicchini S, Tourlaki A. Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy. J Dermatolog Treat 2006; 17:190.</a></li><li><a class="nounderline abstract_t">García-Navarro X, Garcés JR, Baselga E, Alomar A. Linear porokeratosis: excellent response to photodynamic therapy. Arch Dermatol 2009; 145:526.</a></li><li><a class="nounderline abstract_t">Salas T, Hernandez-Gil J, Lopez A, et al. Two cases of disseminated superficial actinic porokeratosis treated with daylight-mediated photodynamic therapy. Dermatol Ther 2016; 29:484.</a></li><li><a class="nounderline abstract_t">Ferrer Guillén B, Giácaman MM, Pérez Ferriols A. Improved effect on 2 cases of disseminated superficial actinic porokeratosis with daylight photodynamic therapy. Photodiagnosis Photodyn Ther 2018; 23:365.</a></li><li><a class="nounderline abstract_t">Ramelyte E, Bylaite-Bucinskiene M, Dummer R, Imhof L. Successful Use of Grenz Rays for Disseminated Superficial Actinic Porokeratosis: Report of 8 Cases. Dermatology 2017; 233:217.</a></li><li><a class="nounderline abstract_t">Ting S, Webster M. Grenz ray therapy in disseminated superficial actinic porokeratosis: A case series of 17 patients. Australas J Dermatol 2022; 63:91.</a></li><li><a class="nounderline abstract_t">McCallister RE, Estes SA, Yarbrough CL. Porokeratosis plantaris, palmaris, et disseminata. Report of a case and treatment with isotretinoin. J Am Acad Dermatol 1985; 13:598.</a></li><li><a class="nounderline abstract_t">Hong JB, Hsiao CH, Chu CY. Systematized linear porokeratosis: a rare variant of diffuse porokeratosis with good response to systemic acitretin. J Am Acad Dermatol 2009; 60:713.</a></li><li><a class="nounderline abstract_t">Garg T, Ramchander, Varghese B, et al. Generalized linear porokeratosis: a rare entity with excellent response to acitretin. Dermatol Online J 2011; 17:3.</a></li><li><a class="nounderline abstract_t">Gutierrez EL, Galarza C, Ramos W, et al. Facial porokeratosis: A series of six patients. Australas J Dermatol 2010; 51:191.</a></li><li><a class="nounderline abstract_t">Howard M, Hall A. A report and follow up of a patient with disseminated superficial actinic porokeratosis (DSAP) undergoing novel systemic treatment with palifermin (a keratinocyte growth factor) during chemotherapy. Dermatol Online J 2018; 24.</a></li><li><a class="nounderline abstract_t">Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol 2005; 152:518.</a></li><li><a class="nounderline abstract_t">Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med 2015; 373:1618.</a></li><li><a class="nounderline abstract_t">Rongioletti F, Rebora A. Disseminated porokeratosis with fatal metastatic squamous cell carcinoma: an additional case of "malignant disseminated porokeratosis". Am J Dermatopathol 2002; 24:144.</a></li><li><a class="nounderline abstract_t">Sawai T, Hayakawa H, Danno K, et al. Squamous cell carcinoma arising from giant porokeratosis: a case with extensive metastasis and hypercalcemia. J Am Acad Dermatol 1996; 34:507.</a></li><li><a class="nounderline abstract_t">Lozinski AZ, Fisher BK, Walter JB, Fitzpatrick PJ. Metastatic squamous cell carcinoma in linear porokeratosis of Mibelli. J Am Acad Dermatol 1987; 16:448.</a></li><li><a class="nounderline abstract_t">Anzai S, Takeo N, Yamaguchi T, et al. Squamous cell carcinoma in a renal transplant recipient with linear porokeratosis. J Dermatol 1999; 26:244.</a></li></ol></div><div id="topicVersionRevision">Topic 13721 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115203" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25115203" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Porokeratoses: an update of clinical, aetiopathogenic and therapeutic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055013" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A report of 31 cases of porokeratosis at the National Skin Centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059828" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22571584" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Porokeratosis in Singapore: an Asian perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25120591" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical analysis and etiology of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26223374" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Imiquimod and Photodynamic Therapy Are Useful in the Treatment of Porokeratosis in Children with Bone Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20451293" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Disseminated superficial actinic porokeratosis co-existing with linear and verrucous porokeratosis in an elderly woman: Update on the genetics and clinical expression of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10844547" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification of a locus for disseminated superficial actinic porokeratosis at chromosome 12q23.2-24.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12366408" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A novel locus (DSAP2) for disseminated superficial actinic porokeratosis maps to chromosome 15q25.1-26.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18443824" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of a genetic locus for autosomal dominant disseminated superficial actinic porokeratosis on chromosome 1p31.3-p31.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21161278" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A novel locus for disseminated superficial actinic porokeratosis maps to chromosome 16q24.1-24.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25180256" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Exome sequencing identifies SLC17A9 pathogenic gene in two Chinese pedigrees with disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29722423" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mutations in mevalonate pathway genes in patients with familial or sporadic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22983302" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23834120" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Identification of three novel frameshift mutations of the MVK gene in four Chinese families with disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27422687" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26202976" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Genomic variations of the mevalonate pathway in porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11766876" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The structure and function of nuclear lamins: implications for disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28765912" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Disorder of the mevalonate pathway inhibits calcium-induced differentiation of keratinocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15482473" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A novel locus for disseminated superficial porokeratosis maps to chromosome 18p11.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20456383" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fine mapping of the disseminated superficial porokeratosis locus to a 2.7 Mb region at 18p11.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12932230" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Identification of a locus for porokeratosis palmaris et plantaris disseminata to a 6.9-cM region at chromosome 12q24.1-24.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19632740" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mibelli revisited: a case of type 2 segmental porokeratosis from 1893.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30942823" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Second-Hit, Postzygotic PMVK and MVD Mutations in Linear Porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4864722" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Disseminated superficial actinic porokeratosis (DSAP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2584454" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Disseminated superficial actinic porokeratosis: experimental induction and exacerbation of skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29606833" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Disseminated Superficial Actinic Porokeratosis in a Vitiligo Patient Undergoing Treatment with Long-Term Narrowband Ultraviolet B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27741114" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mycosis fungoides patient accompanied actinic keratosis, actinic keratosis with squamous cell carcinoma transformation, and porokeratosis after NBUVB therapy - 1st case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6490996" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Disseminated superficial "actinic" porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1428428" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Porokeratosis in immunosuppressed and nonimmunosuppressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8737872" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Porokeratosis of Mibelli and HIV-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9068727" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High incidence of porokeratosis in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650158" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Porokeratosis of Mibelli following bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2642639" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Porokeratosis of mibelli in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9854155" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Porokeratosis and immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1737691" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Porokeratosis of Mibelli following heart transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25800103" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Eruptive disseminated porokeratosis associated with corticosteroid-induced immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21929548" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Porokeratosis: present concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037793" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Eruptive disseminated porokeratosis: a new classification system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7917997" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Disseminated superficial porokeratosis in a patient with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Immunosuppression-induced porokeratosis of Mibelli: Complete regression of lesions upon cessation of immunosuppressive therapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463472" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Disseminated superficial porokeratosis: complete remission subsequent to discontinuation of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16872477" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Porokeratosis of Mibelli induced by topical corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18191708" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Segmental porokeratosis after radiation therapy for follicular lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8959909" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Disseminated superficial porokeratosis developing after electron-beam total skin irradiation for mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894772" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Porokeratosis arising in a burn scar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7701882" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Porokeratosis of Mibelli associated with active chronic hepatitis and vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1761774" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Linear and punctate porokeratosis associated with end-stage liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18258333" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044835" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Synchronous development of disseminated superficial porokeratosis and hepatitis C virus-related hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722052" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Porokeratosis and Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33210788" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Drugs associated with development of porokeratosis: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36515632" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Histopathologic findings of drug-induced eruptive porokeratosis under nivolumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36320094" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Disseminated superficial actinic porokeratosis following hydroxyurea treatment: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2721409" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Facial presentation of disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29194784" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Inflammatory disseminated superficial porokeratosis successfully controlled with a combination of topical diclofenac gel and systemic etretinate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7756155" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Porokeratosis and immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537558" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Disseminated epidermolytic acanthoma with disseminated superficial porokeratosis and verruca vulgaris in an immunosuppressed patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9012935" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Disseminated superficial porokeratosis after autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534661" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Sudden onset of disseminated porokeratosis of Mibelli in a renal transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15230892" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Giant porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21860162" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Giant porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393956" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Different morphological variants of hypertrophic porokeratosis and disseminated lesions of porokeratosis of Mibelli: a rare co-existence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616847" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypertrophic perianal porokeratosis in association with superficial actinic porokeratosis of the leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10202676" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vulvar porokeratosis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8566987" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Genital porokeratosis of Mibelli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29271370" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Acral porokeratosis associated with anonychia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29232434" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Linear porokeratosis associated with multiple squamous cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086492" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Linear porokeratosis with multiple squamous cell carcinomas successfully treated by electrochemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17673390" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Multicentric Bowen disease in linear porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9267731" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Cancer proneness of linear porokeratosis may be explained by allelic loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21163173" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Porokeratosis plantaris, palmaris, et disseminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2943230" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Porokeratosis plantaris, palmaris, et disseminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948055" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A case of porokeratosis plantaris palmaris et disseminata and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6237133" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Porokeratosis plantaris palmaris et disseminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2474014" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Porokeratosis palmaris et plantaris disseminata: an unusual clinical presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2525006" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Porokeratosis punctata palmaris et plantaris. A new entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2933431" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Porokeratosis punctata palmaris et plantaris (punctate porokeratosis). Case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055860" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Porokeratosis ptychotropica: a lesser-known variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022531" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Porokeratosis ptychotropica: a clinically distinct variant of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24274427" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Porokeratosis ptychotropica: a rare and evolving variant of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24945649" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Porokeratosis ptychotropica: a rare variant of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21899589" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Genitogluteal porokeratosis involving the scrotum: an unusual presentation of an uncommon disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29750048" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Genitogluteal porokeratosis: a clinical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26500866" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Penoscrotal porokeratosis: A distinct entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19891931" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Genital porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21933257" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Exclusive facial porokeratosis: histopathologically showing follicular cornoid lamellae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21712691" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Follicular porokeratosis on the face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20559115" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Facial follicular porokeratosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26126043" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Follicular porokeratosis of the nose: two further cases of an emerging variant of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17074001" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Eruptive pruritic papular porokeratosis: a pruritic variant of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1377721" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Eruptive pruritic papular porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9407190" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Disseminated superficial porokeratosis: an eruptive pruritic papular variant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29706025" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Disseminated filiform hyperkeratosis - a variant of porokeratosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9733036" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Familial craniosynostosis, anal anomalies, and porokeratosis: CAP syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15924278" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Characterization of a new syndrome that associates craniosynostosis, delayed fontanel closure, parietal foramina, imperforate anus, and skin eruption: CDAGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624658" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Porokeratosis and cutaneous malignancy. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15949029" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Common skin cancers in porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1097326" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Porokeratosis [correction of Parakeratosis] Mibelli and skin carcinoma: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576684" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Fatal squamous cell carcinoma arising from transplant-associated porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491759" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Porokeratosis large skin lesions are susceptible to skin cancer development: histological and cytological explanation for the susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16684305" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Coexistence of three variants of porokeratosis with multiple squamous cell carcinomas arising from lesions of giant hyperkeratotic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34077570" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Dermoscopy of porokeratosis: results from a multicentre study of the International Dermoscopy Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20536654" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Hyperkeratotic variant of porokeratosis Mibelli with dermal amyloid deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652111" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Disseminated Superficial Porokeratosis with Dermal Amyloid Deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26894774" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Pigmented Porokeratosis. A Further Variant?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7246969" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Cornoid lamellation. A histologic reaction pattern.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15545557" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Dermoscopy of disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18289344" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Disseminated superficial actinic porokeratosis diagnosed by dermoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768494" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Open pores with plugs in porokeratosis clearly visualized with the dermoscopic furrow ink test: report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21680280" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Dermoscopic features in disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153357" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Clinical and dermoscopic features of porokeratosis of Mibelli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24011977" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Circumscribed palmar or plantar hypokeratosis 10 years after the first description: what is known and the issues under discussion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113926" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Cutaneous sarcoidosis simulating porokeratosis of Mibelli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25255914" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Porokeratotic adnexal ostial naevus: review on the entity and therapeutic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19664847" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Widespread porokeratotic adnexal ostial nevus: clinical features and proposal of a new name unifying porokeratotic eccrine ostial and dermal duct nevus and porokeratotic eccrine and hair follicle nevus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6617251" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Disseminated superficial porokeratosis: rapid therapeutic response to 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4732842" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Fluorouracil ointment treatment of porokeratosis of Mibelli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6826793" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Porokeratosis (Mibelli): treatment with topical 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3710530" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : [Linear Mibelli's porokeratosis. Treatment with topical 5-fluorouracil].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28283894" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Treatment of Porokeratosis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616497" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Porokeratosis of Mibelli: successful treatment with topical 5% imiquimod cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17092865" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Porokeratosis of Mibelli of the axillae: treatment with topical imiquimod.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21507038" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16487129" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Successful treatment of porokeratosis of Mibelli with imiquimod 5% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239156" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Case of linear porokeratosis: successful treatment with topical 5% imiquimod cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903259" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16396815" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Disseminated porokeratosis palmaris and plantaris treated with imiquimod cream to prevent malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16792657" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Human papillomavirus isolated from transplant-associated porokeratoses of mibelli responsive to topical 5% imiquimod cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16865875" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Successful treatment of porokeratosis with topical imiquimod in 2 immunosuppressed cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22070709" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Porokeratosis of Mibelli: Involution and resolution with 5% imiquimod cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16471466" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A case of extensive linear porokeratosis with evaluation of topical tretinoin versus 5-flourouracil as treatment modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16961514" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Generalized linear porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14636214" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Topical tretinoin in Indian male with zosteriform porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25035379" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Calcipotriol and adapalene therapy for disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071323" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Disseminated superficial actinic porokeratosis: treatment with topical tacalcitol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20860745" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Successful treatment of disseminated superficial actinic porokeratosis with tacalcitol lotion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8313653" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Disseminated superficial actinic porokeratosis responding to calcipotriol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18554227" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Treatment of disseminated superficial actinic porokeratosis with topical diclofenac gel: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18702625" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Diclofenac sodium 3% gel as a potential treatment for disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34028808" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Topical simvastatin-cholesterol for disseminated superficial actinic porokeratosis: An open-label, split-body clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36947042" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Safety and Efficacy of Topical Lovastatin Plus Cholesterol Cream vs Topical Lovastatin Cream Alone for the Treatment of Disseminated Superficial Actinic Porokeratosis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21199636" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Porokeratosis of Mibelli: Successful treatment with 5 percent topical imiquimod and topical 5 percent 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404225" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Treatment of porokeratosis of mibelli with combined use of photodynamic therapy and Fluorouracil cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14594607" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Porokeratosis plantaris, palmaris, et disseminata.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996406" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Treatment of porokeratosis with fluorouracil and salicylic acid under occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24124851" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Treatment of porokeratosis of Mibelli with cantharidin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24553841" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Long-term clearance of linear porokeratosis with tacrolimus, 0.1%, ointment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468843" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Linear porokeratosis of mibelli: successful treatment with cryotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10792809" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : A scaly macule on the bridge of the nose of a 15-year-old boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18174807" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Facial porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229539" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Linear porokeratosis: successful treatment with diamond fraise dermabrasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519933" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Successful treatment of porokeratosis of Mibelli with diamond fraise dermabrasion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3086391" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Linear porokeratosis: treatment with the carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445104" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Treatment of porokeratosis of Mibelli with CO2 laser vaporization versus surgical excision with split-thickness skin graft. A comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3102571" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Carbon dioxide laser in the treatment of porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7971564" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Porokeratosis of Mibelli: rapid recurrence of a large lesion after carbon dioxide laser treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18025379" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Fractional photothermolysis: a novel treatment for disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18078407" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Successful treatment of disseminated superficial actinic porokeratosis with Q-switched ruby laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18569267" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Treatment of disseminated superficial actinic porokeratosis (DSAP) with the Q-switched ruby laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11050503" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Treatment of lichen amyloidosis (LA) and disseminated superficial porokeratosis (DSP) with frequency-doubled Q-switched Nd:YAG laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23927405" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Erbium laser for the treatment of disseminated superficial actinic porokeratosis: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22148053" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Photodynamic Therapy Combined with CO(2) Laser Vaporization on Disseminated Superficial Actinic Porokeratosis: A Report of 2 Cases on the Face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472551" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Topical photodynamic therapy in disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18429984" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Photodynamic therapy in disseminated superficial actinic porokeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16854765" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Successful treatment of disseminated superficial actinic porokeratosis with methyl aminolevulinate-photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451495" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Linear porokeratosis: excellent response to photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27502333" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Two cases of disseminated superficial actinic porokeratosis treated with daylight-mediated photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076993" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Improved effect on 2 cases of disseminated superficial actinic porokeratosis with daylight photodynamic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28817832" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Successful Use of Grenz Rays for Disseminated Superficial Actinic Porokeratosis: Report of 8 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34905626" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Grenz ray therapy in disseminated superficial actinic porokeratosis: A case series of 17 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2934437" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Porokeratosis plantaris, palmaris, et disseminata. Report of a case and treatment with isotretinoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293030" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Systematized linear porokeratosis: a rare variant of diffuse porokeratosis with good response to systemic acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21635825" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Generalized linear porokeratosis: a rare entity with excellent response to acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20695858" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Facial porokeratosis: A series of six patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29630163" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : A report and follow up of a patient with disseminated superficial actinic porokeratosis (DSAP) undergoing novel systemic treatment with palifermin (a keratinocyte growth factor) during chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787821" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488693" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11979075" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Disseminated porokeratosis with fatal metastatic squamous cell carcinoma: an additional case of "malignant disseminated porokeratosis".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609268" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Squamous cell carcinoma arising from giant porokeratosis: a case with extensive metastasis and hypercalcemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819092" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Metastatic squamous cell carcinoma in linear porokeratosis of Mibelli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10343471" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Squamous cell carcinoma in a renal transplant recipient with linear porokeratosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
